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It is well known that exercise contributes to the beneficial regulation of glycaemic 
control. However, the dose-response relationship between exercise and glycaemic 
control is currently unclear. This study therefore aimed to identify the dose-response 
relationship between exercise and glycaemic control. 
Methods 
A clinical trial was carried out where participants were required to carry out four 
doses of exercise (0, 175, 350 and 700 kcal) to investigate the impact of each dose 
of exercise on glycaemic control. Due to the Covid-19 pandemic this clinical trial is 
still ongoing.  
A meta-analysis and meta-regression were carried out to investigate the effects of 
exercise dose on glycaemic control. Volume and intensity were used as modifiers in 
the meta-regression to analyse their association. 
Results 
The clinical trial is still in its early stages due to the Covid-19 pandemic, but research 
so far has suggested that 350 kcal of exercise could improve glycaemic control 24hrs 
post-exercise when compared to no exercise.  
The meta-analysis shows that an exercise programmes improve glycaemic control 
and BMI in participants with type 2 diabetes. The meta-regression shows no 
statistically significant associations between the two variables volume and intensity, 
however, there could be a potential trend between volume and HbA1c. 
Conclusions 
The meta-analysis and meta-regression show that exercise positively benefits 
glycaemic control. The volume of exercise may be important when investigating the 
optimal dose of exercise required to treat type 2 diabetes as an association between 
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2.1. What is type two diabetes? 
Type 2 diabetes occurs when cells no longer respond properly to insulin (loss of 
insulin sensitivity) and this is accompanied by inadequate secretion of insulin to 
compensate as the disease progresses and β cells fail (Colberg et al., 2010). It 
occurs in response to chronic hyperglycaemia which results in insulin resistance and 
eventual pancreatic β cell dysfunction, disrupting the overall metabolic homeostasis 
in the body (Hameed et al., 2015). These two factors, insulin resistance at target 
tissues and impaired insulin secretion from β cells, are the main features of type 2 
diabetes (Hameed et al., 2015). Type 2 diabetes results from a combination of 
genetic and environmental factors but genetic factors are unable to account for the 
rapid increase in recent years (Tuomi et al., 2014). The genes specific to an 
individual may determine how susceptible they are to the modifiable environmental 
factors (Dietrich et al., 2019). An individual’s environment, for example, physical 
activity, diet, and stress levels, are likely to either counteract or enhance certain 
genes individuals have which may predispose them to a higher risk of type 2 
diabetes (Dietrich et al., 2019). Therefore, it is thought that environmental factors are 
more important when investigating this global epidemic (Tuomi et al., 2014). 
 
2.2. Prevalence of type two diabetes- 
The number of people with diabetes has more than doubled in the last 20 years 
(Zimmet et al., 2014) and type 2 diabetes accounts for around 90% of all diagnosed 
diabetes cases (Saeedi et al., 2019). In 2019, 9.3% of the adult population were 
diagnosed with diabetes (Saeedi et al., 2019). Those with the disease are at risk of 
multiple pathologies. They experience a two to three-fold increase in the risk of heart 
attacks and strokes (Sarwar et al., 2010). Diabetes is one of the leading causes of 
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kidney failure (Collins et al., 2015) and 2.6% of global blindness occurs in those with 
the disease (Bourne et al., 2013). It is predicted that, due to the ageing population, by 
2038 there will be 20% more cases than there was in 2000 (Bagust et al., 2002) and 
in 2017, diabetes contributed to 1.8% of global gross domestic product (Bommer et 
al., 2017). Diabetes will pose a major clinical and financial challenge to the NHS with 
the annual cost hospital services for those with diabetes estimated to be around £3bn 
in 2019 (Stedman et al., 2020). Due to the ageing population, the economic burden 
of this cost is likely to be unfairly and disproportionately supported by the decreasing 
economically productive age groups (Bagust et al., 2002). 
2.3. Risk factors 
 
There are both modifiable and non-modifiable risk factors of diabetes; non-modifiable 
risk factors including age, genetics and ethnicity (Bellou et al., 2018). It is the 
modifiable risk factors which primarily contribute to the pathogenesis of the disease. 
These include body mass index (BMI), physical inactivity, poor nutrition, 
hypertension, smoking and alcohol use (Bi et al., 2012). Physical inactivity and poor 
nutrition help contribute to higher BMI, and it is the higher dietary glycaemic load and 
trans-fat intake which is associated with this that contributes to increased diabetes 
risk (Kyrou et al., 2020). Three hours of TV viewing per day has detrimental effects 
on overall health and considerably increases the risk of type 2 diabetes (Patterson et 
al., 2018), and those who participate in recommended levels of moderate exercise 
reduce their risk of developing diabetes by 26% (Mayor, 2016). Although moderate 
consumption of alcohol has been shown to decrease risk of diabetes, heavy drinkers 
have an increased risk (Bi et al., 2012). Type 2 diabetes risk is also 3.27 times higher 
in individuals that smoke (Campagna et al., 2019). Nicotine exposure from smoking 
has also been shown to cause beta-cell dysfunction and apoptosis (Bi et al., 2012). 
Certain psychosocial factors also show evidence of increasing the risk of diabetes, 
this includes depression, increased stress and lower social support (Deshpande et 
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al., 2008). Research has found that those who have a history of a major depressive 
disorder experience a two-fold increase in the risk of diabetes (Arroyo et al., 2004).  
2.4. Pathophysiology of diabetes 
 
The feedback system between the β cell and insulin sensitive tissues tightly regulates 
glucose homeostasis (Scheen, 2003). In healthy individuals, β cells are stimulated to 
release insulin so that insulin can then mediate the uptake of glucose, amino acids, 
and fatty acids into tissues (Kahn et al., 2014). A large majority of people suffering 
from type 2 diabetes are obese, with central visceral adiposity (Scheen, 2003) and 
there is an inverse linear relationship between BMI and the age at which type 2 
diabetes is diagnosed (Galicia-Garcia et al., 2020). The adipose tissue in obese 
individuals helps to promote insulin resistance (Galicia-Garcia et al., 2020). This is 
due to various inflammatory mechanisms, including an increase in free fatty acid 
release and adipokine deregulation (Galicia-Garcia et al., 2020). When insulin 
resistance is present, the β cells must increase the concentration of insulin released 
to maintain glucose uptake (Kahn et al., 2014) (Figure.2).  Glucotoxicity, lipotoxicity 
and glucolipotoxicity are also present in obese individuals, and all of these factors 
help induce metabolic and oxidative stress which damages β cells (Galicia-Garcia et 
al., 2020). Glucotoxicity is caused by an excess of glucose which has detrimental 
effects on cells (Kaiser et al., 2003), lipotoxicity results from lipid accumulation in 
non-adipose tissue (Engin, 2017) and glucolipotoxicity is the combination of both 
which results extremely harmful effects on cells and tissues (Weir, 2020). β cell 
dysfunction means that β cells cannot sustain the increased insulin output needed to 
maintain glucose homeostasis (Kahn et al., 2014). This causes plasma glucose 
levels to rise and the magnitude of β cell dysfunction correlates to the degree of 
elevation in glucose concentration (Kahn et al., 2014). β-cell deficit and β-cell 
apoptosis further develop in those with type 2 diabetes as the disease progresses, 
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and along with insulin resistance and impaired insulin secretion, this disrupts the 
homeostasis in which insulin communicates with cells (Scheen, 2003). 
2.5. Metabolism in healthy individuals 
2.5.1. Glucose stimulated insulin secretion 
 
Insulin, along with glucagon, is a key regulator of glucose homeostasis, and the 
intracellular network of insulin secretion is multifactorial. High concentrations of 
plasma glucose initiate an adenosine triphosphate (ATP)-sensitive potassium (K+) 
channel-dependent mechanism which causes insulin to be initially secreted 
(Komatsu et al., 2013). A K+-ATP channel-independent mechanism then gradually 
takes over. Insulin is secreted by β-cells in the islets of Langerhans of the endocrine 
pancreas (Kulkarni, 2004). When plasma glucose concentrations increase, glucose 
enters cells through the glucose transporter 4 (GLUT-4) (Navale & Paranjape, 2016). 
Once in the cytoplasm, glucokinase phosphorylates glucose to glucose-6-phosphate 
(Karwi et al., 2020). Glucose-6-phosphate then enters the glycolytic pathway to 
produce pyruvate (Ahmed, 2016). This pathway subsequently produces ATP. 
Pyruvate dehydrogenase and pyruvate carboxylase metabolise pyruvate and transfer 
it to the mitochondria for the tricarboxylic acid cycle to take place (Figure 1) (Komatsu 
et al., 2013). The transfer of pyruvate is also associated with the efflux of tricarboxylic 
cycle intermediates (Komatsu et al., 2013). 
Glycolysis causes the concentration of ATP to increase, this results in ATP-sensitive 
K+ channels closing and membrane depolarisation occurring (Ahmed, 2016). L-type 
voltage-dependent calcium (Ca2+) ion channels open, due to the change in 
membrane voltage, causing an influx of Ca2+ and therefore an elevation of free 
cytosolic Ca2+ concentration (Komatsu et al., 2013). It is this Ca2+ influx which 
stimulates the rapid exocytosis of insulin from granule stores near the cell membrane 
(Trexler & Taraska, 2017). The magnitude of this first phase secretory response is 
dependent on the size of the granules (Ahmed, 2016). Insulin secretion is only 
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sustained if it is further stimulated by metabolizable secretagogues, and other 
granule stores deeper within the β cell must be utilised (Ahmed, 2016; Komatsu et 
al., 2013). ‘Fusion and replenishment’ is a way the biphasic response of insulin can 
be viewed because readily releasable granules of insulin near the cell membrane are 
replenished by reserve pools (Figure 1) (Komatsu et al., 2013). It is thought that the 
time dependent increase of insulin in response to high glucose concentration is 
triggered by a number of metabolic stimuli, such as mitochondrial intermediates, 









Figure 1. Glucose stimulated insulin secretion. 
A high concentration of glucose within the plasma activates ATP-K+ channels on the 
plasma membrane of β cells and this initiates insulin secretion at the first stage 
(Ahmed, 2016). Glucose enters the cell via GLUT 4 and the glycolytic pathway 
begins to eventually produce pyruvate. Increases in ATP due to glycolysis and the 
TCA cycle close ATP-K+ sensitive channels which results in membrane 
depolarisation (Ahmed, 2016). This depolarisation causes Ca2+ channels to open and 
rapid influx of Ca2+ occurs. This increase in concentration of Ca2+ activates the rapid 
exocytosis of insulin from a readily releasable pool of granules (Ahmed, 2016). The 
2nd stage allows insulin secretion to be sustained by a reserve pool (Ahmed, 2016). 
[Redrawn and modified from: (la Vega-Monroy & Fernandez-Meji, 2011)] 
 
When high glucose concentrations are sustained, both proinsulin biosynthesis and 
islet amyloid polypeptide (IAAP) concentrations increase (Röckl et al., 2008). This 
causes an increase in the production of reactive oxygen species caused by the 
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accumulation of misfolded insulin and IAAP (Röckl et al., 2008). These factors 
contribute to the alteration of endoplasmic reticulum Ca2+ mobilisation (Röckl et al., 
2008). They also increase proapoptotic signalling and degradation of proinsulin 
mRNA due to the activation of the apoptotic protein response pathway induced 
through endoplasmic reticulum stress (Röckl et al., 2008).  Interleukin-1 beta (IL-1β) 
release is also induced; this recruits macrophages contributing to immune 
dysregulation and increases local islet inflammation (Asano, 2014). The literature 
states that these factors all help contribute to the disruption of islet integrity, impair 
cell-to-cell communication, and subsequently, contribute to the worsening of 
hyperglycaemia (Galicia-Garcia et al., 2020). 
It is the increasing dysfunction of beta cells which allows impaired glucose tolerance 
(a fasting blood glucose concentration of 6.1mmol/L and above (NICE, 2017)) to 
progress to type 2 diabetes (a fasting blood glucose concentration of 7.0mmol/L and 
above (NICE, 2017)) (Kahn et al., 2014). A range of environmental factors contribute 
to this progression, age, nutrition, and a sedentary lifestyle, are just a few examples. 
Beyond the age of 30, the human pancreas is unable to keep renewing β cells and 
therefore loss of beta-cells, such as due to glucolipotoxicity, explains why there is an 
increased risk of type 2 diabetes with age (Kahn et al., 2014).  
However, even though type 2 diabetes was previously thought to only occur in the 
middle aged and elderly, the onset of the disease is now becoming even more 
prevalent in those under the age of 30 years old (Lin et al., 2020). This is thought to 
be due to increases in sedentary lifestyles and the adoption of western diets resulting 
in higher rates of obesity in the younger population (Alberti et al., 2004). Central 
visceral adiposity associated with obesity is an important determinant of 
hyperinsulinemia which occurs during the early stages in the development of type 2 
diabetes (Alberti et al., 2004; Martín-Timón et al., 2014). It is therefore the 
industrialisation and globalisation of society inducing these changes in lifestyle which 
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have contributed to obesity and type 2 diabetes becoming more prevalent in the 
younger generation (Alberti et al., 2004). If preventative measures and effective 
treatments aren’t put in place, then this will have significant impacts on workforce and 
healthcare systems when individuals are burdened with the effects of the disease 
(Alberti et al., 2004). Understanding the doses of exercise which help regulate 
glycaemic control and provide effective prevention or treatment for type 2 diabetes is 
therefore likely to have significant beneficial impacts on society. 
2.5.2. The effect of insulin on target tissues 
 
Insulin binds to specific receptors on the plasma membrane of target cells to initiate 
an anabolic response and due to changes in nutrient concentrations, a signalling 
pathway is activated (Petersen & Shulman, 2018). Insulin can cause diverse 
physiological responses depending on the cell type it binds to and this variation in 
response is likely to underpin the pathogenesis of insulin resistance (Haeusler et al., 
2018). The insulin receptor (INSR) is a heterotetrametric receptor tyrosine kinase 
with two extracellular α subunits which bind insulin and two β subunits which span 
the membrane, each subunit containing a tyrosine kinase domain (Petersen & 
Shulman, 2018). The two α binding sites have negative cooperativity so only one 
insulin molecule binds at a time (Petersen & Shulman, 2018). 
When insulin binds to the receptor it induces a conformational change in the 
membrane spanning β-subunit (Haeusler et al., 2018). This causes the cis-
autoinhibition in the kinase activation loop to be released allowing trans-
autophosphorylation of the tyrosine’s in the activation loop (Petersen & Shulman, 
2018). Further tyrosine phosphorylation occurs in the juxtamembrane region and this 
is important for the recruitment of substrates (Petersen & Shulman, 2018).  
Mitogenic and metabolic signals can both be produced from the activation of the 
insulin receptor due to the activation of several phosphotyrosine binding proteins 
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(Petersen & Shulman, 2018). Most metabolic effects of insulin result from activation 
of the phosphoinositide 3-kinase (PI3K) pathway, connected exclusively by the 
phosphotyrosine binding protein- insulin receptor substrate (IRS) (Skyler, 2020). This 
allows the conversion of the tyrosine phosphorylation signal into a lipid kinase signal 
(Haeusler et al., 2018). The mitogen activated protein kinase (MAPK) pathway is 
involved in the regulation of gene expression and involves both IRS and Shc 
(Petersen & Shulman, 2018). Mitogenesis and differentiation are controlled by a 
combination of these pathways (Skyler, 2020). 
In the metabolic pathway, IRS proteins have specific phosphotyrosine binding (PTB) 
domains and NH2-terminal homology which assist the proteins in targeting INSRs 
when activated (Petersen & Shulman, 2018). The PTB domain of IRS binds to 
pTyr972 of INSR and this allows INSR to phosphorylate a number of tyrosine residues 
on IRS (Petersen & Shulman, 2018). Once this phosphorylation has occurred, the 
PI3K pathway is initiated. The p85 or p55 regulatory subunits of PI3K bind to IRS 
which activates the p110 catalytic subunit of the heterodimer (Petersen & Shulman, 
2018), (Skyler, 2020). The catalytic subunit then catalyses the production of 
phosphatidylinositol-3,4,5-triphosphate (PIP3) from phosphatidylinositol-3,4,5-
biphosphate (PIP2) (Haeusler et al., 2018; Petersen & Shulman, 2018). The 
generation and accumulation of PIP3 helps to localise downstream signalling 
effectors by recruiting phosphoinositide-dependent protein kinases (PDK) (Skyler, 
2020). This activates 3 isoforms of AKT/protein kinase B (PKB) which can activate 
four downstream substrates critical to metabolism (Skyler, 2020). These are mTOR-
involved in the regulation of lipid and protein synthesis, Glycogen synthase kinase 3 
(GSK3)-involved in the regulation of glycogen synthesis, Forkhead Family Box O 
(FOXO) transcription factors- involved in glucose production vs utilisation and 
regulation of gluconeogenic and adipogenic genes, and AS160/TBC1D1-involved in 
regulating glucose transport (Figure 2) (Haeusler et al., 2018; Skyler, 2020). 
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Following food consumption there is an increased risk of postprandial 
hyperglycaemia and glucose disposal into muscle plays a major part in reducing this 
risk. The glucose transporter GLUT4 is stored in vesicles close to the plasma 
membrane (Skyler, 2020). It is the PI3K/PDK/AKT insulin signalling pathway which 
phosphorylates the AS160/TBC1D1 substrates and initiates the translocation of the 













Figure 2. Insulin signalling and its downstream effectors. 
Insulin binds to its receptor, INSR, which causes tyrosine phosphorylation and a 
conformational change of the receptor (Petersen & Shulman, 2018). This activates 
IRS which converts the tyrosine phosphorylation signal into a lipid kinase signal via 
recruitment of PI3K (Haeusler et al., 2018). This enzyme catalyses the production of 
PIP3 which ultimately activates AKT (Petersen & Shulman, 2018). Once activated 
ATK phosphorylates the substrates, FOXO, mTOR, GSK3 and TBCD1/AS160 via 
their Ser/Thr residues which activates a range of mechanisms involved in glucose 
uptake, utilisation and production, glycogen synthesis, and lipid and protein synthesis 
(Haeusler et al., 2018). [Diagram redrawn and modified with information from: 
(Haeusler et al., 2018)] 
2.5.3. The role of incretins in glucose homeostasis 
 
The incretin hormones are released from enteroendocrine cells into the blood after a 
meal is consumed. After oral glucose intake, they are responsible for 50% of the total 
secretion of insulin (Kim & Egan, 2008). The incretin hormones consist of glucose-
dependent insulinotropic peptide (GIP) and glucagon-like peptide 1 (GLP-1), both of 
which exhibit glucose dependent insulinotropic activity (Kim & Egan, 2008). This 
means the effect they have on the pancreas brings about a three-fold amplification of 
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glucose induced insulin release and the hormones alone do not cause 
hypoglycaemic episodes (Ahmed, 2016).  
GIP is synthesised and released from K cells present in the jejunum and duodenum 
of the small intestine, and food containing glucose or fat stimulates its release 
(Ahmed, 2016). GIP binds to its specific receptor (GIPR) on β cells (Kim & Egan, 
2008). This binding is positively coupled to increases in intracellular cyclic adenosine 
monophosphate (cAMP) and Ca2+ levels which mediate a rise in insulin secretion (W. 
Kim & Egan, 2008), (Ahmed, 2016). GIP also has other roles, it is involved in fat 
metabolism at adipocytes, helps to moderate fatty acid synthesis, enhances the 
insulin simulated conversion of fatty acids into triglycerides and promotes beta-cell 
proliferation and cell survival (Kim & Egan, 2008).  
GLP-1 is a product of the post-translational cleavage of the proglucagon gene (Kim & 
Egan, 2008) and is one of the most potent insulin secretagogues (Ahmed, 2016). It is 
released from L cells in the mucosa of the ileum and colon (Ahmed, 2016). It exists in 
multiple forms; 80% of the biologically active circulating GLP-1 is the COOH-
terminally amidated form- GLP-1 (7-36) and the glycine extended form- GLP-1 (7-37) 
is found in much lower concentrations (Ørskov et al., 1986). In a similar way to GIP, it 
binds to its specific receptor on β cells and this binding is coupled to increases in 
cAMP and Ca2+ concentrations which cause an increase in insulin (Ahmed, 2016). 
GLP-1 is also involved in gastric emptying, inhibits glucagon secretion and slows the 
rate of endogenous glucose production (Kim & Egan, 2008). Treatment of those with 
type 2 diabetes with GLP-1 has been found to be successful in normalising blood 
glucose levels, improve beta-cell function and can help to restore first-phase insulin 





2.5.4. Secretagogues and insulin secretion 
 
Insulin secretagogues can be endogenous biological agents, exogenous compounds 
from plants or artificially synthesised pharmacological agents (Hemmingsen et al., 
2016). They stimulate the release of insulin and are therefore commonly used as a 
pharmacological treatment for diabetes. There are two main classes; sulphonylureas 
and meglitinide analogues (Hemmingsen et al., 2016). Their major primary action is 
causing the closure of ATP sensitive K+ channels (Hemmingsen et al., 2016). This 
coincides with the stimulation of Ca2+ influx into islet cells and therefore contributes to 
the increased secretion of insulin. Although secretagogues are a common treatment 
for type 2 diabetes to stimulate the release of insulin, research has found that their 
use might further ameliorate the problem of β cell dysfunction associated with the 
disease and therefore cause the worsening of the problems caused by type 2 
diabetes in the longer term (Russo et al., 2014). Using exercise as a treatment to 
regulate glycaemic control could therefore be an extremely beneficial alternative to 
individuals with the disease. 
2.5.5. Lipid metabolism in healthy individuals 
 
After ingestion of a meal containing fat, the exogenous lipoprotein pathway is 
initiated. It begins with the incorporation of triglycerides into chylomicrons in the 
intestine, and they are released into circulation via the thoracic duct (Klop et al., 
2013), (Feingold, 2000). Once the chylomicrons reach muscle and adipose tissue, 
they utilise lipoprotein lipase (LPL) as a docking station (Feingold, 2000). The 
triglycerides are metabolised by LPL into free fatty acids (FFA) and 2-
monoacylglycerols (MAG) (Klop et al., 2013). These molecules can then be taken up 
by both passive diffusion and specific transporters into enterocytes, and results in 
chylomicron remnants being formed (Feingold, 2000). LPL is strongly expressed in 
tissues which require larger amounts of FFA for energy production. 
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The endogenous lipoprotein pathway begins in the liver via the synthesis of 
triglyceride-rich very low-density lipoproteins (VLDL). VLDL and chylomicron 
synthesis is very similar but VLDL uses APO B100 as the structural protein whereas 
chylomicrons use APO B48 (Feingold, 2000; Klop et al., 2013). VLDL also uses LPL 
as a docking station for the metabolism of triglycerides for uptake into cells (Klop et 
al., 2013). This forms intermediate-density lipoprotein (IDL) which is further 
metabolised into low-density lipoprotein (LDL) (Feingold, 2000). LDL is enriched with 
cholesterol, carrying the majority of cholesterol in circulation which therefore makes it 
extremely pro-atherogenic (Feingold, 2000).  
High density lipoprotein (HDL) plays a major role in reverse cholesterol transport 
(Feingold, 2000). These particles acquire cholesterol and phospholipids after their 
efflux from cells. This occurs via the transporter ABCA1 which allows the formation of 
mature HDL (Feingold, 2000). Once the cholesterol and phospholipids have been 
acquired by HDL, cholesterol becomes esterified (Klop et al., 2013). Transfer to the 
liver then occurs either directly or indirectly via interaction with hepatic SR-BI or via 
transfer of cholesterol to VLDL/LDL by cholesterylester-transfer protein respectively 
(Klop et al., 2013). During the transfer of cholesterol esters to VLDL/LDL, HDL gains 
triglycerides in a direct exchange (Klop et al., 2013). Due to its role in reverse 
cholesterol transport, HDL is anti-atherogenic and also has other benefits such as an 
anti-inflammatory, anti-apoptotic and antioxidant properties (Krauss, 2004). 
2.6. Metabolism in those with type 2 diabetes 
2.6.1. Insulin resistance 
 
Insulin resistance occurs when the biological effect of insulin on cells is lower than 
what is required to maintain glucose homeostasis (Ormazabal et al., 2018). The 
impact of insulin resistance varies depending on the physiological function of the 
tissues which interact with it and how much they rely on insulin to control their 
metabolic processes (Ormazabal et al., 2018), (Sowers & Frohlich, 2004). Insulin 
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resistance has major impacts on skeletal muscle, adipocytes, and liver tissues as 
they rely heavily on insulin to regulate their high metabolic demand (Ormazabal et al., 
2018). Skeletal muscle is responsible for around 75-80% of glucose uptake and 
therefore the presence of insulin resistance within these cells has a huge impact on 
increasing hyperglycaemia (DeFronzo & Tripathy, 2009). Higher concentrations of 
insulin are required to elicit a normal response when insulin resistance is present 
(Ormazabal et al., 2018) (Figure 3). In skeletal muscle, hyperinsulinemia within the 
plasma, which occurs as a response to reduced insulin sensitivity, further reduces 
insulin sensitivity within these cells (DeFronzo & Tripathy, 2009). It therefore has a 
negative impact rather than the intended benefit of maintaining glucose uptake 
(DeFronzo & Tripathy, 2009). Research has shown that even hyperinsulinemia 
induced in healthy individuals for 72-96hrs, contributed to a significant reduction in 
insulin-stimulated glucose disposal by around 30-40% in skeletal muscle (impaired 
nonoxidative glucose disposal) due to increasing the insulin resistance of the tissue 
(DeFronzo & Tripathy, 2009). This demonstrates that compensatory hyperinsulinemia 
aims to counteract some of the effects of insulin resistance, but can also ameliorate 
the effects of insulin resistance in skeletal muscle (DeFronzo & Tripathy, 2009).  As 
diabetes progresses, β cells fail due to prolonged hyperglycaemia and insulin 
production is therefore reduced (Bar-Tana, 2020) (Figure 3). A range of risk factors 
contribute to an individual developing insulin resistance, including obesity and a 









Figure 3. Insulin and Glucose trends as type 2 diabetes progresses. 
In normal individuals, the fasting plasma glucose is <6.1mmol/L and HbA1c 
concentrations <6%, with little insulin resistance present (NICE, 2017). In individuals 
with prediabetes, glucose concentration increases between 6.1-6.9mmol/L and 
HbA1c concentrations between 6%-6.4% (NICE, 2017). As soon as insulin resistance 
increases and insulin sensitivity decreases, insulin concentration increases to try and 
compensate for the lack of sensitivity (Bar-Tana, 2020). Glucose concentrations 
increase in individuals with type 2 diabetes, and they have glucose concentrations 
>6.9mmol/L and HbA1c ≥6.5% (NICE, 2017). [Own figure with information from: (Bar-
Tana, 2020)] 
 
Obesity is associated with an increase in fatty acids which contribute to lipid 
accumulation (Ormazabal et al., 2018; Saini, 2010). One theory which links obesity to 
the development of insulin resistance is that an increased concentration of fatty acids 
could lead to an activation of an atypical protein kinase cascade (PKC) (Dresner et 
al., 1999). This would contribute to the inhibition of insulin signalling and therefore 
reduce insulin-stimulated glucose uptake, particularly in skeletal muscles (Figure 4) 
(Dresner et al., 1999; Ormazabal et al., 2018). The activation of  PKC causes the 
serine phosphorylation of insulin receptor subtrate-1 (IRS-1) labelling it for 
ubiquitination and degradation (Figure 5) (Lasram et al., 2014; Saini, 2010). Recent 
evidence suggests that the serine phosphorylation of IRS proteins reduces the ability 
of the IRS proteins to attract PI3-kinase (Saini, 2010). This minimises the activation 
of this molecule and decreases IRS-1 tyrosine phosphorylation, further impairing 
signalling to downstream effectors  (Ormazabal et al., 2018).  
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These signalling defects caused by obesity may also be altered by the increased 
concentrations of several protein tyrosine phosphatases (PTPs), such as PTB1B and 
LAR (Kahn & Flier, 2000). These proteins propagate tyrosyl phosphorylation events 
which dephosphorylate and contribute to the termination of signalling activity (Kahn & 
Flier, 2000). There is evidence that the expression and activity of at least three PTPs 
is increased in those who are obese. Research has specifically shown that LAR and 
PTB1B activity increases, contributing to the dephosphorylation of the insulin 
receptor (Kahn & Flier, 2000). 
Research also suggests that those who are obese experience an increased 
expression of the p85-α subunit of PI3-kinase (Saini, 2010). This alters the balance 
between the PI3-kinase subunits which significantly impacts the ability of insulin to 
stimulate the p85-p110 heterodimer to associate effectively with IRS-1 (Saini, 2010). 
This is another factor which contributes to the reduction of PI3-kinase insulin 
signalling and therefore reduces insulin sensitivity.  
These alterations in insulin signalling occur in both adipose and muscle cells, but 
some of the molecular defects may be tissue specific (Kahn & Flier, 2000). There is 
evidence that in adipose tissue, IRS-1 expression is significantly reduced which 
decreases the availability of IRS-1 for PI3K to use as a docking protein (Kahn & Flier, 
2000). Whereas, in skeletal muscle, the availability of IRS-1 remains normal but the 
actual association of IRS with PI3K is significantly altered (Figure 4) (Kahn & Flier, 
2000). Both of these factors reduce insulin sensitivity. 
The location of fat deposits in those who are obese has been found to influence the 
risk of insulin resistance. Central fat deposits are more strongly linked to developing 
insulin resistance (Kahn & Flier, 2000). One suggestion as to why this is the case is 
due to intra-abdominal adipocytes being more lipolytically active. This is likely to 
contribute to increases in free fatty acid levels and this could inhibit insulin clearance, 
although the exact mechanisms are currently uncertain (Kahn & Flier, 2000). A high 
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fat diet and an increase in the supply of fatty acids, increases the concentrations of 
the bioactive lipids: diacylglycerols (DAGs) and ceramides (Sokolowska & Blachnio-
Zabielska, 2019). The excess lipid concentration due to a high fat diet is initially 
stored in adipose tissue, and this could be one of the reasons why a high amount of 
central visceral adiposity is strongly linked to type 2 diabetes (Sokolowska & 
Blachnio-Zabielska, 2019). Once adipose tissue has reached capacity, the lipids start 
to be stored in non-adipose tissue, such as skeletal muscle and the liver, causing 
organ dysfunction through lipotoxicity (Sokolowska & Blachnio-Zabielska, 2019). 
Research has shown DAGs and ceramides, may also play a major role in hepatic 
insulin resistance (Petersen & Shulman, 2017). The liver is responsible for 90% of 
glucose production and therefore a lack of glucose regulation, due to the decreased 
insulin sensitivity of the tissue, has major implications on the development and 
progression of type 2 diabetes (Petersen & Shulman, 2017).  DAGs are thought to 
play a mechanistic role by activating protein kinase C (PKC) which then 
phosphorylates the insulin receptor, inhibiting insulin receptor tyrosine kinase activity 
(Petersen & Shulman, 2017). This inhibits overall hepatocellular insulin signalling, 
preventing downstream signalling and regulation from occurring (Petersen & 
Shulman, 2017).  
Ceramides accumulate due to an increased availability of fatty acids 
(Sokolowska & Blachnio-Zabielska, 2019). The mechanisms of how ceramides are 
associated with hepatic insulin resistance are currently under debate (Petersen & 
Shulman, 2017). It is thought that ceramides either impair the translocation of or 
inactivate protein kinase B (AKT) so it can no longer participate in the insulin pathway 
(Petersen & Shulman, 2017). Some research suggests that ceramides activate PKC 
which prevents the translocation of AKT to the plasma membrane (Salinas et al., 
2000). Other research suggests ceramides might activate protein phosphatase 2A 
which causes the dephosphorylation and deactivation of AKT (Zhou et al., 1998). 
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Evidence has also shown that ceramides increase the activation of proinflammatory 
cytokines, promote hepatic lipid accumulation and contribute to inducing the 
apoptotic pathway of β cells (Sokolowska & Blachnio-Zabielska, 2019). All of these 
factors contribute to hepatic insulin resistance and even though the exact 
mechanisms aren’t well understood, it is clear that ceramides are associated with 
insulin resistance. These two bioactive lipids, diacylglycerols and ceramides, are 
therefore an example of two major players in the development of type 2 diabetes. 
Reduced glucose transport into cells is another major factor which contributes to the 
effects of increased insulin resistance experienced by those with type 2 diabetes. 
Evidence shows that in adipocytes, GLUT4 is downregulated which impairs insulin 
stimulated glucose uptake (Kahn & Flier, 2000). Adipose tissue produces adipokines 
which can alter glucose concentrations (Saini, 2010). Specifically, TNF-α is released 
which contributes to this down regulation of GLUT4 in adipose tissue and increases 
insulin resistance (Saini, 2010). This is different to skeletal muscle cells, where 
GLUT4 expression remains normal but defective transport is present instead (Kahn & 
Flier, 2000). This is related to the impaired translocation, docking or fusion of GLUT 4 
vesicles to the specific plasma membrane (Kahn & Flier, 2000).  
JNK, PKC and IKK are three major kinases which cause the serine phosphorylation 
of IRS and its subsequent ubiquitination and degradation (Figure 4) (Lasram et al., 
2014). They are activated by hyperinsulinemia, hyperglycaemia, and dyslipidaemia, 
all of which are features of type 2 diabetes. Hyperglycaemia results in the production 
of both AGEs and ROS (Lasram et al., 2014). AGEs interact with the AGE receptor 
which can either result in the direct inhibition of IRS or activate the three major 
kinases to phosphorylate IRS (Lasram et al., 2014). ROS contribute to the overall 
REDOX disturbance within the cell and contributes to the activation of the three 
kinases (Lasram et al., 2014). As discussed above, an increase in fatty acids, due to 
dyslipidaemia, can activate PKC directly or indirectly via DAG and ceramides to 
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contribute to the phosphorylation of IRS (Lasram et al., 2014). All of these factors 
contribute to increasing insulin resistance in those with type 2 diabetes as 
downstream insulin signalling is unable to be activated when ubiquitination and 
degradation of IRS prevents the pathway from being maintained (Figure 4). 
Activation of JNK and IKK by these factors also initiates signalling pathways which 
activate the transcription factors API and NF- κB (Lasram et al., 2014). These 
transcription factors cause the increased transcription of genes which contribute to 
reduced insulin sensitivity (Figure 4) (Lasram et al., 2014). 
All of the factors discussed above, contribute to the reduced insulin sensitivity and 
increased insulin resistance individuals experience in the development of type 2 
diabetes. The variety and range of tissues impacted by insulin resistance, and the 
effects this has on the body, is one of the reasons individuals with type 2 diabetes 










Figure 4. The cellular and molecular mechanisms of insulin resistance. 
JNK, PKCθ and IKK are important kinases which play significant roles in the 
metabolic responses within the cell. They contribute to the serine 
phosphorylation of IRS-1 which leads to its subsequent degradation, 
preventing downstream signalling (Lasram et al., 2014). Free fatty acids and 
pro-inflammatory cytokines, such as IL-6 and IL-1β contribute to the activation 
of the kinases. Hyperglycaemia increases AGE and ROS concentrations. 
AGEs interact with the AGE receptor and this can directly inhibit IRS-1 
(Lasram et al., 2014). ROS contributes to the disturbance of redox status in 
the cell contributing to insulin resistance (Lasram et al., 2014). [Redrawn and 
modified from (Lasram et al., 2014)] 
2.6.2. Measures of glucose concentrations and diabetes diagnosis 
 
Glycated haemoglobin (HbA1c) is the gold standard measure for both the diagnosis 
and prognosis of diabetes by the American Diabetes Association (Sherwani et al., 
2016). Glycation occurs when glucose binds to the N-terminal of haemoglobin in a 
non-enzymatic irreversible reaction (Sherwani et al., 2016). HbA1c is therefore a 
reliable measure of the cumulative glucose history of the individual for the previous 2-
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3months due to the half-life of a red blood cell being around 12 weeks (Sherwani et 
al., 2016). Increases in HbA1c are directly proportional to increases in blood glucose 
concentrations and can also act as a prognosis predictor due to its correlation with 
long term risk (Sherwani et al., 2016). If HbA1c measurements are unable to be 
taken, then fasting blood glucose concentrations can act as a secondary measure. 
Fasting blood glucose, however, only shows blood glucose concentrations at a 
specific point in time, therefore isn’t reliable for indicating a longer-term trend and can 
be impacted by day-to-day changes such as stress (Ghazanfari et al., 2010). 
The oral glucose tolerance test (OGTT) is another method of diagnosing diabetes 
and examining blood glucose concentrations (Jagannathan et al., 2020). It measures 
blood glucose concentrations for a 2hr period after a glucose load (Jagannathan et 
al., 2020). It helps to determine how quickly glucose can be cleared from the blood 
and it can therefore be used as an indirect measure of insulin resistance and β-cell 
function (Jagannathan et al., 2020). However, this test is time consuming for the 
patient and also sensitive to day-to-day variations such as exercise and stress 
(Jagannathan et al., 2020). 
 
2.6.3. Type 2 Diabetes and Lipid Metabolism 
 
Obesity greatly alters lipid metabolism, resulting in dyslipidaemia. Those with obesity 
typically have increased fasting and post-prandial triglycerides, and an increase in 
small dense LDL along with reductions in HDL-C (Klop et al., 2013). Obesity induces 
a reduction in mRNA expression levels of LPL resulting in reduced LPL activity in 
adipose tissue. There is therefore increased competition between chylomicrons and 
VLDL for the lipolysis of triglycerides (Klop et al., 2013). This causes a reduction in 
the clearance of triglyceride-rich lipoproteins, and along with the increased hepatic 
production of VLDL particles, results in increased serum triglyceride levels (Repas, 
2011). HDL-C levels are also typically lower in those with obesity which means the 
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transfer of cholesterol to VLDL/LDL in return for triglycerides is unable to occur 
(Feingold, 2000), further increasing serum triglyceride levels (Repas, 2011). The 
triglycerides present on LDL are then hydrolysed by hepatic lipase which produces 
small dense LDL (Repas, 2011).  
A combination of obesity and insulin resistance causes an increased efflux of fatty 
acids from adipose tissue and impairs the uptake of free fatty acids into skeletal 
muscle (Krauss, 2004). This increases the delivery of fatty acids to the liver (Krauss, 
2004). The increased concentration of fatty acids is then utilised in the synthesis of 
triglycerides (Repas, 2011). An abundance of triglycerides prevents Apo B-100 from 
being degraded which results in the increased formation and secretion of VLDL 
(Repas, 2011). The increased secretion of VLDL contributes to the increased 
concentration of serum triglycerides (Repas, 2011).  
Another factor which increases triglyceride levels in those with type 2 diabetes, is the 
reduced activity of lipoprotein lipase. A lack of insulin-induced stimulation of 
lipoprotein lipase reduces the degradation of triglycerides and increases Apo-C-III 
levels which the further inhibits lipoprotein lipase (Repas, 2011). A meta-analysis 
found that a 1mmol/L increase in serum triglyceride, increases coronary disease risk 
by 32% in men and 76% in women (Hokanson & Austin, 1996). The increase in 
serum triglycerides is just one of the factors that contributes to an increased risk of 
cardiovascular diseases in those with type 2 diabetes. 
Another factor that increases serum triglyceride levels is the proinflammatory state 
induced by obesity due to an increase in macrophages that infiltrate adipose tissue 
and the resultant increase in pro-inflammatory cytokines, TNF, and IL-1 (Repas, 
2011). Inflammation is known to be a major player in the development of 
atherosclerosis which promotes thrombosis, both of which increase the risk of 
developing cardiovascular disease (Meerarani et al., 2006). TNF and IL-1 help 
stimulate the lipolysis of triglycerides in adipose tissue, contributing to the increased 
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circulation and delivery of fatty acids to the liver (Repas, 2011). This results in the 
increased production and secretion of VLDL (Yuan et al., 2007). These cytokines 
also reduce the expression of lipoprotein lipase, reducing the degradation of 
triglycerides within circulation (Repas, 2011; Yuan et al., 2007), further contributing to 
the increased concentration of triglycerides. It is thought that triglycerides are very 
pro-atherogenic and may contribute to the increased formation of arterial-wall foam 
cells, increasing the risk of cardiovascular disease in those with type 2 diabetes 
(Yuan et al., 2007). 
HDL metabolism is also effected by these pro-inflammatory cytokines which 
decreases reverse cholesterol transport and contributes to cholesterol accumulation 
increasing atherosclerosis (Repas, 2011). There is a direct correlation between 
reduced HDL-C levels and increased cardiovascular disease risk (Rader & Hovingh, 
2014). HDL have a range of beneficial effects including direct cardioprotective 
effects, increasing cellular cholesterol efflux, and direct antioxidative and anti-
inflammatory properties (Krauss, 2004). Those with type 2 diabetes, have reduced 
HDL concentrations and therefore experience a reduction in these benefits, 
increasing cardiovascular disease risk. 
Whether individuals with type 2 diabetes experience increased concentrations of 
LDL, which also contribute to the increased risk of cardiovascular diseases, is 
currently under debate. However, evidence shows that those with type 2 diabetes are 
more likely to have LDL with increased density and reduced size which results in the 
particles becoming more atherogenic (Krauss, 2004). These LDL have a reduced 
affinity for LDL receptors, they enter the subendothelial space much more easily, 
they can bind strongly to arterial wall proteoglycans and the particles experience 
increased susceptibility to oxidative modifications (Repas, 2011), (Krauss, 2004). The 
oxidative modifications increase the likelihood of uptake of LDL into macrophages 
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(Repas, 2011). All of these factors of small dense LDL contribute to increased arterial 
wall damage, increasing the risk of cardiovascular disease. 
2.7. Common morbidities 
 
Diabetes unfortunately effects range of different organ systems within the body, and 
it is this which causes the multiple morbidities experienced by sufferers. They 
experience a much higher prevalence of microvascular complications including 
neuropathy, nephropathy, and retinopathy, but also experience macrovascular 
complications, such as cardiovascular disease, stroke and peripheral vascular 
disease (Deshpande et al., 2008). 10,000 new cases of blindness result from diabetic 
retinopathy every year which makes it one of the most common microvascular 
complications (Deshpande et al., 2008). It is the morbidities associated with diabetes 
which increase the mortality rate. Cardiovascular disease, for example, causes 65% 
of deaths in all people with diabetes (Deshpande et al., 2008). People with type 2 
diabetes are also 15 times more likely to have a lower leg amputation (Deshpande et 
al., 2008) due to peripheral neuropathy and peripheral arterial disease. Therefore, 
effective treatments, such as lifestyle interventions, are needed to reduce the 
symptoms, expenses, life expectancy and quality of life of those with type 2 diabetes. 
2.8. Cardiovascular disease 
 
Cardiovascular disease is a serious morbidity associated with insulin resistance and 
type 2 diabetes, as it accounts for the majority of deaths in individuals with type 2 
diabetes (Ormazabal et al., 2018). The risk of developing cardiovascular disease 
increases two to eight-fold in those with type 2 diabetes (Martín-Timón et al., 2014). It 
is thought that hyperglycaemia and insulin resistance are the main protagonists 
(Ormazabal et al., 2018). Research has suggested that the risk of cardiovascular 
disease increases by around 18% with only a 1 unit increase in glycosylated 
haemoglobin (HbA1c) (Selvin et al., 2004). There are two main factors which cause 
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cardiovascular disease, these are atheroma formation, and ventricular hypertrophy 
(Feingold, 2000). Hyperinsulinemia occurs as a result of insulin resistance and this 
excess insulin upregulates the cluster differentiation protein 36, an important free 
fatty acid transporter (Su & Abumrad, 2009). This increases the intracellular free fatty 
acid concentration of cardiomyocytes and contributes to the heart becoming 
saturated in a fatty acid and glucose environment (Kolwicz et al., 2013). As the 
severity of insulin resistance increases, the heart’s ability to utilise free fatty acids 
decreases (Grynberg & Demaison, 1996). This results in intramyocardial lipid 
accumulation which negatively impacts the functioning of the heart through 
apoptosis, impaired mitochondrial function, cardiac hypertrophy, and contractile 
dysfunction (Goldberg et al., 2012). All of these factors contribute to increasing the 
risk of cardiomyopathy and heart failure.  
An increase in the amount of visceral fat mass due chronic caloric excess associated 
with obesity contributes to the hypertrophy of individual adipocytes (Longo et al., 
2019). This results in the increased release of chemotactic factors including 
monocyte chemoattractant protein-1 (MCP-1) and TNF-α (Ormazabal et al., 2018). 
MCP-1 is involved in the migration and differentiation of monocytes into 
macrophages within visceral adipose tissue (Ormazabal et al., 2018). The 
macrophages then secrete TNF-α which initiates a chain of events, involving 
triglyceride biosynthesis and adipocyte storage, resulting in an increase in plasma 
triglyceride concentrations (Guilherme et al., 2008). It is then hypothesised that this 
results in ectopic lipid deposition in extra-adipose tissue (Ormazabal et al., 2018). In 
the heart, this increases the volume of epicardial adipose tissue which is associated 
with a range of negative impacts, including an increase in the mass within both 
ventricles, resulting in ventricular hypertrophy and therefore contractile dysfunction 
(Fitzgibbons & Czech, 2014). 
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Hyperglycaemia and obesity are thought to significantly contribute to an increased 
risk of atheroma formation. Advanced glycation end (AGE) products, which are non-
enzymatic glycation products of lipids and proteins, are produced due to the 
presence of hyperglycaemia (Nowotny et al., 2015). These molecules damage the 
integrity and structure of the endothelium by accumulating in vessel walls, increasing 
an individual’s risk of developing atherosclerosis (Nowotny et al., 2015). AGE 
products also play a part in a range of diabetic complications, such as retinopathy 
and neuropathy and also contribute to the development of insulin resistance (Figure 
5) (Nowotny et al., 2015).  
Pro-inflammatory and pro-coagulant factors also increase in the presence of 
hyperglycaemia. This includes increasing the ability of leukocyte cells to associate to 
endothelial cells via adhesion (Kahn & Flier, 2000).  This is another factor which 
induces apoptosis and endothelial damage (Kahn & Flier, 2000). Pro-coagulant factor 
PAI-1 expression increases (Sowers & Frohlich, 2004). This molecule enhances 
platelet aggregation which is evidenced in insulin resistant states (Sowers & Frohlich, 
2004). Endothelin 1 secretion is also elevated when insulin resistance is present in 
an individual (Sowers & Frohlich, 2004). This is a vasoconstrictor and competes with 
nitric oxide (NO) (Sowers & Frohlich, 2004). NO regulates endothelial dependent 
relaxation in the large arteries and is also beneficial in inhibiting platelet aggregation 
(Sowers & Frohlich, 2004). An increase in endothelin 1 secretion therefore 
contributes to increasing the risk of atherosclerosis and therefore cardiovascular 
disease as a result. The range of impacts insulin resistance has on the heart 
contributes to our understanding of why cardiovascular disease risk increases so 




2.9. Exercise training as a treatment for type 2 diabetes 
2.9.1. Acute effects 
 
Insulin and exercise are the two factors which reduce plasma glucose concentrations 
and enhance glucose homeostasis (Colberg et al., 2010). When at rest the body 
requires insulin-dependent mechanisms to control glucose homeostasis (Asano, 
2014). Insulin signalling requires the activation of phosphatidylinositol 3-kinase, 
phosphorylation of the insulin receptor and the insulin receptor substrate (Röckl et 
al., 2008). Exercise doesn’t require any of these pathways and therefore insulin 
resistant tissue will still take up glucose during exercise (Sylow et al., 2017). There 
are three key steps which allow exercise to increase glucose uptake by up to 50%, 
these are delivery, transport across the membrane and oxidation causing intracellular 
influx (Sylow et al., 2017). Delivery of glucose to active muscle cells is increased due 
to a rise in blood flow. This is associated with an increase in capillary recruitment 
which subsequently increases the surface area for the influx of glucose and oxygen 
(Sylow et al., 2017). Oxygen consumption is coupled to blood flow and this ensures 
sufficient glucose reaches active muscle tissue (Sylow et al., 2017). 
Exercise also causes the translocation of the GLUT4 transporter to the muscle cell 
membrane. There have been a number of signalling pathways implicated in this 
process, including the use of the proteins: AMP-activated protein kinase (AMPK), 
Ca2+/calmodulin-dependent protein kinases and protein kinase C (Röckl et al., 2008). 
During muscle contraction, AMPK activity increases significantly (Asano, 2014) and 
evidence has suggested that there is a positive correlation between AMPK activity 
and glucose uptake (Röckl et al., 2008). It is thought that AMPK is a major sensor of 
intracellular energy status and helps balance cellular energy supply and demand 
through regulation of anabolic and catabolic pathways (Kjøbsted et al., 2018).  
Intracellular Ca2+ concentrations increase significantly during muscle contraction 
(Röckl et al., 2008). Ca2+/calmodulin-dependent protein kinases which regulate this 
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increase have also play a critical role in glucose transport via GLUT4 into the 
contracting muscle cells (Röckl et al., 2008).  Evidence has also found that the 
GLUT4 target genes are upregulated due the increases in Ca2+ (Chin, 2005). The 
increased translocation of GLUT4 (Figure 5), allows the permeability of the muscle 
cells to increase in regards to glucose influx. Once glucose enters the cell, it is used 
in either aerobic or anaerobic mechanisms, depending on the intensity and volume of 
exercise (Hargreaves & Spriet, 2020). The enzyme hexokinase phosphorylates 
glucose to produce glucose-6-phosphate (Sylow et al., 2017). The production of 
glucose-6-phosphate preserves the diffusion gradient for facilitated diffusion to occur 
and also traps glucose within the cell (Sylow et al., 2017).  
All of these factors induced during exercise allow glucose to be up taken into muscle 
cells, reducing the concentration of plasma glucose and therefore helping to reduce 
hyperglycaemia (Asano, 2014). This therefore means exercise can be used as a non-
pharmacological method to regulate glucose homeostasis in those with type 2 
diabetes. Although the immediate metabolic effects of exercise are significant, they 
begin to fade in around 24 hours (Kirwan et al., 2017). Regular exercise therefore 






Figure 5. Exercise and insulin stimulated GLUT 4 translocation. 
 Exercise increases the translocation of GLUT4 to the skeletal muscle membrane 
and induces muscle contraction which increases intracellular calcium (Ca2+) content 
(Stanford & Goodyear, 2014). Both the signalling pathways of exercise and insulin 
stimulated glucose uptake converge at two molecules; TBC1D1 and AS160 which 
regulate the translocation of GLUT4 (Stanford & Goodyear, 2014). All of these factors 
and signalling pathways contribute to the increased uptake of glucose in response to 
exercise via the increased translocation of GLUT 4 to the plasma membrane. [Figure 
redrawn and modified from (Stanford & Goodyear, 2014)] 
 
2.9.2. Chronic effects 
 
Evidence has shown that chronic exercise training can improve body composition by 
increasing energy expenditure. This therefore reduces visceral fat, if calorie intake is 
kept constant or reduced, resulting in a reduced burden on heart and lungs (O’Hagan 
et al., 2013). Regular exercise causes muscle growth, increasing muscle mass 
(Pearson, 1990). This increases the uptake of glucose as skeletal muscle is 
responsible for 75-80% of glucose uptake and glucose can also then be utilised 
quicker to produce energy for contracting muscles (DeFronzo & Tripathy, 2009). 
Chronic exercise also has benefits on insulin resistance and glycosylated 
haemoglobin levels. Even as little as one week of exercise training can improve 
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insulin sensitivity in type 2 diabetes patients (O’Hagan et al., 2013). Regular training 
increases both the expression and activity of proteins involved in insulin signalling 
pathways (Colberg et al., 2010), therefore improving tissue sensitivity. One clinical 
trial has found that insulin sensitivity improves by around 25-35% after just 6 weeks 
of regular physical activity (Koivisto & Yki-Järvinen, 1986).  
Those with type 2 diabetes have increased concentrations of plasma glucose and 
lipids (Colberg et al., 2010). Regular exercise gradually consumes both glucose and 
lipids to help counteract the negative effects of high concentrations of both types of 
molecules (Yang et al., 2019). This helps to alleviate the glucotoxicity and lipotoxicity 
experienced by pancreatic beta cells, reducing inflammation and oxidative stress on 
tissues (Yang et al., 2019). This allows for the recovery of damaged beta cells and 
acts to protect functional islets (Yang et al., 2019), improving or at least preventing 
the worsening of endocrine function (Yang et al., 2019). Researchers have found that 
12-16 weeks of aerobic exercise in type 2 diabetics, significantly improves β cell 
function (Yang et al., 2019).  
Those with type 2 diabetes typically have increased levels of both triglycerides and 
LDL and low levels of HDL cholesterol (Yang et al., 2019). All these factors contribute 
to an increased risk of cardiovascular disease (Krauss, 2004). Chronic exercise 
increases the concentration of catecholamines (Yang et al., 2019) and increases the 
activity of lipoprotein lipases (Wang & Xu, 2017). This results in lipids being 
hydrolysed into fatty acids which can then be utilised by mitochondria within cells 
(Yang et al., 2019). This helps to reduce the risk of cardiovascular disease which is 
one of the most significant comorbidities associated with type 2 diabetes. 
Cardiovascular complications of type 2 diabetes are thought to be caused by both 
metabolic dysregulation and chronic inflammation (Karstoft & Pedersen, 2016). IL-1β 
is proinflammatory mediator of β-cell damage and therefore a direct cause of β-cell 
dysfunction (Karstoft & Pedersen, 2016). The phosphorylation dysfunction of insulin 
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signal transduction protein is caused by macrophage accumulation and chemotaxis 
which are also key indicators of inflammation (Yang et al., 2019). As chronic exercise 
reduces the accumulation of visceral fat, which is more inflamed than subcutaneous 
fat, it provides anti-inflammatory effects (Karstoft & Pedersen, 2016). It also helps to 
inhibit the accumulation and aggregation of macrophages, and reduces the 
production of cytokines, all of which contribute to inflammation (Yang et al., 2019).  
Levels of the major proinflammatory molecule, C-reactive protein is also significantly 
reduced when exercise is maintained (Kirwan et al., 2017). This therefore means that 
chronic exercise helps to maintain functional insulin signalling and reduces the risk of 
cardiovascular complications in those with type 2 diabetes.  
Exercise has benefits on the immune system (da Silveira et al., 2021) which helps to 
reduce the risk of disease and infection in those with type 2 diabetes. It also helps to 
improve the psychological state, including reducing rates of anxiety and depression 
in sufferers (Yang et al., 2019). 
2.10. Understanding the effects of different doses of exercise on 
glycaemic control 
 
Exercise interventions are often recommended for the improvement of (general) 
physical and mental health. For example, the American Diabetes Association 
suggests that individuals with type 2 diabetes should undertake 150 mins of 
moderate-vigorous exercise at least 3 times per week (Colberg et al., 2010). This, 
however, doesn’t consider intraindividual heterogeneity and differences in 
physiological and functional capacity. Therefore, understanding the dose-response 
relationship of exercise in improving glycaemic control in those with type 2 diabetes 
would hopefully maximise the efficiency and effectiveness of exercise programmes 
(Mann et al., 2013). It is well known that regular physical activity helps improve 
glycaemic control, however, the dose (frequency, intensity, duration) required to 
achieve an effective response is currently unknown (Savikj & Zierath, 2020)F.  
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There is contradictory evidence as to what dose of exercise might be most effective. 
For example, a recent systematic review (Moxley & Bugaieski, 2019), stated that the 
majority of studies found improvements in HbA1c irrespective of exercise intensity. 
Whereas a clinical trial found that, despite high intensity interval training (HIIT) being 
45% lower in training volume than a continuous endurance protocol, individuals 
participating experienced similar or even better improvements in glycaemic control 
(Winding et al., 2018). This specific research therefore suggests that high intensity 
exercise could be a more time-efficient treatment (Winding et al., 2018). There are 
also similar debates around the optimal frequency and volume of exercise sessions 
within a programme. A meta-analysis investigated the association of volume of 
exercise with improvements in glycaemic control (Umpierre et al., 2011). Eighteen 
studies were included within the meta-analysis and the analysis indicated that 
aerobic exercise ≥150 minutes/week was associated with a reduction in HbA1c of 
0.89%, whereas ≤150 minutes/week was only associated with a 0.36% reduction in 
HbA1c  (Umpierre et al., 2011). Similar research also discovered that moderate 
(55%) and high (79%) intensity exercise resulted in similar reductions (Umpierre et 
al., 2013). However, this poses the question as to whether it is the lower volume of 
high intensity interval training that is the limiting factor contributing to the lack of 
improvement in glycaemic control seen in this research (Umpierre et al., 2013). 
Another randomised control trial investigating the relationship of exercise volume 
indicated that there was a significant association between an increase in the volume 
of exercise and a subsequent decrease in HbA1c concentrations (Nicolucci et al., 
2012).  
Another factor to consider when determining the optimal dose of exercise to be 
included within an exercise programme for those with type 2 diabetes is the likelihood 
of individuals to engage and adhere to the programme. One specific clinical trial 
investigated the effects of energy matched continuous low to moderate intensity 
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exercise compared to moderate to high intensity continuous aerobic exercise 
(Hansen et al., 2009). This research found equal effects in both groups in reducing 
HbA1c concentrations (Hansen et al., 2009). This could indicate that calorised dose 
of exercise may be more useful in determining benefits of exercise on glycaemic 
control. This research also indicates that it might be beneficial to concentrate on 
giving low to moderate intensity exercise programmes to sedentary individuals 
(Hansen et al., 2009). Research has discovered that there is an inverse relationship 
between exercise intensity and the likelihood that individuals adhere to the 
programme (Perri et al., 2002). This means there is typically higher drop-out rates in 
higher intensity programmes (Perri et al., 2002).  This could suggest that 
programmes with a higher frequency or volume of exercise may be more influential 
within an exercise programme.  
Another factor to consider when designing an individual’s exercise programme is 
whether they are likely to be supervised. Supervised exercise is associated with 
significantly greater reductions in HbA1c concentrations (Umpierre et al., 2013). If 
supervision isn’t possible, an understanding of the minimal dose of exercise an 
individual needs to undertake in order to effectively improve glycaemic control would 
be even more important in improving the likelihood that an induvial adheres to the 
programme. 
It seems to be that there is a general consensus within the literature that a small 
dose of physical activity is better than nothing, but more physical activity is also 
better than a small dose (Dubé et al., 2012). Significant improvements in glycaemic 
control and insulin sensitivity have been associated with an exercise dose of ~400 
kcal which is only 40%-50% of suggested guidelines (Dubé et al., 2012). An increase 
in low-intensity daily activity such as going for 15-minute walk significantly improves 
glucose homeostasis after the consumption of a meal (Pahra et al., 2017). Whereas 
a 45-minute session of moderate intensity exercise significantly reduces 
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hyperglycaemia for an entire 24-hour period (Van Dijk, Venema, et al., 2013). This 
therefore shows that low-intensity exercise is beneficial but moderate-intensity 
exercise for longer durations becomes increasingly beneficial. Understanding the 
dose-response relationship between exercise and glycaemic control, with the dose of 
exercise being defined by frequency, intensity, and duration of exercise, will hopefully 
provide an estimation of the responses specific doses of exercise can cause. An 
understanding of this relationship will improve the personalisation and 
individualisation of exercise programmes so that they are better suited to an 
individual’s physiological and functional capacity whilst still contributing to the 
improvement of glycaemic control. 
2.11. Importance of the research 
 
Type 2 diabetes is slowly becoming an epidemic as obesity levels continue to 
increase and this will place a huge clinical and financial burden on society (Bagust et 
al., 2002). Blood glucose-lowering drugs to treat diabetes currently cost the NHS £1bn 
annually (Stedman et al., 2019) and have significant side effects to patients who have 
to rely upon them (Palmer et al., 2016). There are also a number of morbidities 
associated with diabetes and it is these diseases which have the biggest burden on 
the health care services. Indirect costs of diabetes due to morbidities are predicted to 
reach around £22.8bn by 2035 (Hex et al., 2012). It is well understood in the literature 
that exercise can help improve glycaemic control (Colberg et al., 2010; Shambrook et 
al., 2018). Research has also shown that the beneficial effects of exercise on 
glycaemic control in those with type 2 diabetes can be experienced up to 24-48 hours 
post exercise (Van Dijk, Manders, et al., 2013). Exercise also has a range of beneficial 
impacts, such lowering BMI and improving lipid profiles, and this can help reduce the 
risk of individuals developing morbidities associated with the disease (Colberg et al., 
2010). This therefore suggests that exercise could be used as a treatment to improve 
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glycaemic control and also improve the health outcomes of individuals with type 2 
diabetes. 
However, the specific dose of exercise which would provide optimal treatment for 
individuals with the disease is currently unknown (Mann et al., 2013). A better 
understanding of the dose-response relationship between exercise and glycaemic 
control would help identify suitable minimum doses of exercise for individuals. The aim 
of this research was to determine the minimum dose of exercise that would provide 
appropriate glycaemic control by plotting a dose-response curve. If the minimum dose 
of exercise needed to treat type 2 diabetes could be determined when the clinical trial 
progresses, then exercise could be used as a reliable treatment with individuals 
becoming more motivated to exercise. Understanding the dose-response relationship 
of exercise and glycaemic control would help in reducing the costs of the disease, 
reducing the reliance upon pharmacological treatments, and reducing the burden the 
morbidities of the disease place on health care services. This research, if successful, 
could therefore have significant beneficial impacts on society.  
2.12. Aims of the research 
 
One aim of this research was to determine the dose-response relationship between 
exercise and glycaemic control. This was be done by providing individuals with 
different doses of exercise (measured in calories) and analysing their glycaemic 
control 24 hrs after exercise. The results were used to produce a dose-response 
curve which will hopefully help determine the minimum doses of exercise required to 
provide effective glycaemic control in those with type 2 diabetes. Due to the research 
being postponed in the Covid-19 pandemic, a secondary aim was investigated. The 
aim of this research was to carry out a systematic review, including a meta-analysis 
and meta-regression, to examine the effect of different intensities and volumes of 
exercise within exercise programmes on glycaemic control. This will hopefully help 
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develop our understanding about the optimal doses of exercise that should be 
included within personalised exercise programmes used to treat type 2 diabetes. 
Each research aim will help improve our understanding of the dose of exercise which 
is required to provide effective glycaemic control in individuals with type 2 diabetes 
and therefore help improve the effectiveness of using exercise as a treatment. 
 




The aim of the study was to investigate the optimal dose-response relationship 
between exercise and glycaemic control to assist in improving exercise adherence 
and use as a treatment in those with type 2 diabetes. Participants took part in four 
different bouts of cycling expending 0 kcal, 175 kcal, 350 kcal and 700 kcal. The 
protocol was based around the finding that ~70 mins of exercise expending ~350 
kcal at 50% V̇O₂ max improved insulin sensitivity by around 35% the following day 
but the minimal dose of exercise required to provide glycaemic control is currently 
unknown (Newsom et al., 2013).  
The protocol included exercise expending half as many calories (175 kcal), as 
well as twice as many (700 kcal) to help in plotting the dose-response curve. This will 
allow the dose-response relationship between exercise and glycaemic control to be 
accurately modelled. From this, the minimal dose of exercise required for glycaemic 
control can be determined. 
This was a registered interventional clinical trial (NCT04129268) that began in 
October 2020. The trial was based between the Human Performance Laboratory 
(HPL) at Lancaster University and the Royal Lancaster Infirmary, Lancaster. In 
accordance with the Declaration of Helsinki (Version 2013) ethical principles (World 
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Medical Association, 2013), ethical documentation was submitted and approved by 
the NHS research ethics committee (REC Ref: 19/NW/0066) and participant 
recruitment began. 
3.1.2. Participant recruitment 
 
The study aimed to recruit three groups of overweight (BMI ≥ 25kg/m2) males. The 
first two cohorts were healthy individuals split into two age groups (n=9) of 18-30 
years and 40-65 years. The third cohort (n=9) were those with a diagnosis of type 2 
diabetes aged between 18-65 years. The testing only took place on males due to the 
protective effects of oestrogen and a lower number of women with type 2 diabetes 
(Iorga et al., 2017). Unfortunately, due to the Covid-19 pandemic, testing could only 
safely be carried out on healthy male individuals aged 18-30 years with a BMI <25 
kg/m2, who were at a lower risk of serious implications of the virus. This level of 
testing could only begin after ethical approval was reapproved at the end of May 
2021.  
Participants were recruited via word of mouth, advertisements on social media and 
via posters placed in the local area. Members of the public who expressed interest 
were contacted via a phone call to have the protocol explained, making them aware 
of the process, and the inclusion and exclusion criteria was discussed to ensure they 
were suitable candidates. Participants were excluded from the trial if; they were 
outside the age ranges stated above, if candidate felt they were unable to perform 
the physical activity within the protocol, or if they had any of the following diseases: 
cardiovascular disease, peripheral or cerebral vascular disease, muscle disorders, 
renal disorders, liver disease or neurological disease. They were also excluded if 
they took any medication which may effect glycaemic control such as corticosteroids 
or biguanides (Korayem, 2017). After this discussion, participants were emailed a 
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copy of the participant information sheet and given a date for an in-person screening 
to take place. 
Below is a schematic of the protocol the participants followed (Figure 6). The first 
stage was for participants to take part in an in-person screening where a family 
history questionnaire was filled out, anthropometric measurements were recorded, 
and it was ensured that participants were fully comfortable with and understood the 
protocol before appropriate consent was given. 
 
 
Figure 6. A schematic of the protocol. 
The protocol involved an initial screening visit, followed by four exercise visits (0, 
175, 350 and 700kCal). 24 hours after each exercise visit, an oral glucose tolerance 
test (OGTT) took place to identify the effects of each exercise visit on glycaemic 
control. 
 
3.1.3. Participant medical screening 
 
To further assess whether those interested were suitable, they filled in a range of 
health questionnaires, such as family history, if any of the results from this meant the 




participating. A copy of the health questionnaire based on the American College of 
Sports Medicine (ACSM) readiness to exercise criteria is given in the appendices 
(Figure 17) (Riebe et al., 2015). Health status was also assessed by the following 
procedures. This involved an ECG carried out by a Cardiochek device (SECA, CT6i, 
Birmingham, UK) connected to a mobile device (AliveCor, Kardia Mobile, New York 
City, USA) to ensure atrial fibrillation wasn’t present. Blood pressure was measured 
using an automated blood pressure monitor (Omron Healthcare, Version M2, Milton 
Keynes, UK) to ensure levels were within a safe range between 90/60 mmHg and 
140/90 mmHg (NHS. 2019). Finger-tip venous blood samples were taken according 
to the protocol detailed in section 3.1.4 and were analysed by the Biosen Analyser 
(EKF Diagnostics, Biosen, UK) to measure fasting blood glucose and lactate 
concentrations.  
Anthropometric measurements where then taken. First height and weight were 
measured using a stadiometer (SECA, Version 213, Birmingham, UK) and weighing 
scales (SECA, Version 813, Birmingham, UK) respectively. This data was then used 




     (NHS, 2018) 
This could identify if participants were classed as overweight (BMI ≥ 25-30kg/m2). 
Finally, various body composition data was collected using bioelectrical impedance 
scales (TANITA, DC-430 MA P, Manchester, UK), including percentage body fat, 
percentage muscle volume and basal metabolic rate (BMR). 
All these data, including health status, questionnaire response and anthropometric 
measurements were reviewed by one of the research team’s medical doctors to 
ensure it was safe for the volunteer to participate. If approval was given for 
participation, the protocol was explained once more to the participant to ensure they 
were fully informed, they had the opportunity to ask any questions, and written 
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informed consent was obtained. The participant was then assigned a code to ensure 
confidentiality was maintained throughout the protocol and all data was kept in a 
password protected and encrypted Excel (Microsoft, Redmond, USA) file.  
3.1.4. Finger-tip blood sample 
 
The member of the research team carrying out the sample always wore appropriate 
PPE and followed the health and safety protocols of the laboratory. On their non-
dominant hand, the participant’s fingertip where the sample was to be taken was first 
sanitised with an antiseptic wipe and was given the chance to air dry. A lancet (Accu-
check Safe-T-Pro Uno Lancet, Roche Diabetes Care, West Sussex, UK) was then 
used to puncture the skin with one quick deliberate stroke. The first drop of blood 
was wiped away due to potential contamination of that sample. The blood was then 
collected within a capillary tube to be analysed by the Biosen Analyser (EKF 
Diagnostics, Biosen, UK). Once the sample was successfully taken, pressure was 
applied to the wound to prevent further bleeding and a plaster was place on the 
finger. 
3.1.5. Submaximal exercise test 
 
To predict V̇O₂ max, the Ekblom-Bak et al (2012) sub-maximal protocol was used 
(Schultz et al., 2020). Participants were instructed not to perform any 
heavy/prolonged physical activity 48 hours prior to experimentation. Once 
participants arrived at the lab, they were fitted with a heart rate monitor (Polar H10, 
Warwick, UK) around their thorax. The test was conducted on a Corvical CPET cycle 
ergometer (Lode, Groningen, Netherlands). For the 8 minutes of the submaximal 
test, participants were advised to pedal at 60 revolutions per minute (RPM). The 
ergometer was set at a fixed rate of 30 watts (W) for the first 4 minutes of the test. 
For the remaining 4 minutes of the test, the ergometer was set at an individualised 
work rate. This work rate varied between 60 and 200 W depending on the individual 
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and the work rate they perceived to be 13-15 (high exertion) on the Borg rating of 
perceived exertion (RPE) (Borg, 1982). Average heart rate (HR) was recorded for the 
final minute of the individualised work rate stage of testing; HR recordings were taken 
at 3:15, 3:30, 3:45 and 4:00 minutes and then averaged. 
This data was then used to predict V̇O₂ max using the Ekblom-Bak prediction 
equation (Schultz et al., 2020).  
 
Where ΔHR is the difference between the initial HR and the individualised work rate 
average HR, and ΔPO is the difference in work rate (watts) between the two stages. 
V̇O₂ max can then be estimated using the natural logarithm of the value calculated by 
the equation. 
3.1.6. Exercise visits 
The protocol required participants to attend the lab for four exercise visits to complete 
0, 175, 350 and 700 kcal of exercise on the cycle ergometer.  The four exercise visits 
were randomised, and each separated by a 2-week break before the next visit to 
allow participants to recover from the oral glucose tolerance test (OGTT) and ensure 
any effects from the previous exercise visit weren’t still present.  
The cardiopulmonary exercise testing (CPET) equipment (Cortex Metalyzer 3B, 
Leipzig, Germany) uses breath by breath technology to determine the respiratory 
exchange ratio (RER) and V̇O₂ of participants (Chrif et al., 2018). CPET involves an 
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incremental exercise protocol to measure oxygen uptake (V̇O₂) and it is the 
maximum oxygen uptake of an individual which determines their V̇O₂ max (Chrif et 
al., 2018). To improve the ability of individuals with type 2 diabetes completing the 
programme we used a submaximal CPET test to predict V̇O₂ max. V̇O₂ max helps 
give an indication of an individual’s exercise and functional capacity (Albouaini et al., 
2007).  The respiratory exchange ratio (RER) gives an estimation of metabolic events 
and the fuel sources that an individual relies upon at certain stages of exercise by 
measuring a ratio of carbon dioxide output and oxygen uptake (Albouaini et al., 
2007). This provides the data needed to calculate the time of exercise required to 
burn the specific number of calories and the formula which was used to calculate this 
is stated below.   
𝑇𝑖𝑚𝑒 (𝑚𝑖𝑛𝑢𝑡𝑒𝑠) = (





) × 𝑅𝐸𝑅𝑐𝑎𝑙𝑜𝑟𝑖𝑓𝑖𝑐 𝑒𝑞𝑢𝑖𝑣𝑎𝑙𝑒𝑛𝑡  
The V̇O₂ and RER values were recorded manually every 30 seconds between 3 and 
10 minutes at the start of the protocol and the average was taken. The RER calorific 
















Table 1. Table of values used to determine RER calorific equivalent.  
Calorific values for the ratio of oxygen and carbon dioxide from the respiratory 
exchange ratio and the energy contribution from the proportion of carbohydrates and 
fats consumed. [Table retrieved from: (Carpenter, 1933)] 
 
These values were then input into the equation to determine the length of time 
participants needed to cycle for to burn the specific number of calories. All 
participants cycled at the speed corresponding to 60% of their V̇O₂ max, which was 
calculated in the sub-maximal exercise test. 
3.1.7. Physical activity monitoring 
 
Participants were fitted with an exercise tracker, a GENE-Activ tri-axial accelerometer 
(Active Insights, Kimbolton, UK), for 72 hours post exercise visit. Evidence has 
57 
 
shown that the GENE-Activ accelerometer has excellent technical reliability and its 
use in a range of other diabetes related studies has confirmed its validity for use 
within this trial (Bell et al., 2015; Cassidy et al., 2018; Esliger et al., 2011). This was 
set up with their height, weight and age within the lab and was programmed to 
automatically record data as soon as the visit was complete. The purpose of the 
exercise tracker was to monitor their energy expenditure, ensure they were not 
exceeding their designated energy expenditure for three days post visit and provide 
evidence of their typical day-to-day activities. Evidence shows three days is sufficient 
to be an accurate and reliable predictor of weekly activity levels (Dillon et al., 2016). 
3.1.8. Dietary analysis 
 
Participants were also required to record everything they ate in a food diary for the 
day of the exercise visit (the day before the OGTT), including the control meal, and 
for 3 days after the Oral Glucose Tolerance Test (OGTT) visit. This was to assess 
the effects their food consumption could be having on their blood glucose levels 
which may effect and help explain results collected. After every exercise visit, 
participants were given the same standardised meal (Sainsbury’s spinach and ricotta 
tortellini); 736 kcal, carbohydrate=50.3 g, fat=11.6 g, and protein=13.2 g to consume 
that same evening. Participants consumed the meal between 6.00 and 8.00pm after 
which, they were only allowed to consume water until after the OGTT was completed.  
3.1.9. Oral Glucose tolerance test 
 
The morning following the exercise visit, the participants attended the lab in a 12-
hour fasted state for an Oral Glucose Tolerance Test (OGTT). They were seated in a 
semi-supine position on a bed (Plinth 2000, Plinth Medical, Suffolk, UK) and could 
use their mobile device to keep them occupied. Firstly, a finger-tip blood sample was 
taken following the protocol in section 3.1.4, and blood glucose was measured using 
a Biosen Analyser (EKF Diagnostics, Biosen, Cardiff, UK). A blood glucose value of 
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≤5.56 mmol/L indicates that the participant was sufficiently fasted (Moebus et al., 
2011). They had a retrograde venous cannula inserted into the dorsal surface of their 
non-dominant arm by a qualified member of the research team (Figure 7) (Brooks et 
al., 1989; Copeland et al., 1992). It is inserted in the opposite direction to an 
anterograde cannula and therefore allows the collection of distal blood samples 
where arterial venous shunting is more likely to occur (McGuire et al., 1976). The 
participants arm was then placed in a heated box (52°C) for 15 minutes to allow for 
arterialisation of the blood (Brooks et al., 1989). This acts as a less invasive 
alternative to arterial catheterisation but still allows accurate metabolic 
measurements to be collected (McGuire et al., 1976).  A dextrose drink was created 
by dissolving 75 g of dextrose (Bulk Powders, Colchester, UK) in 300 ml of water. A 
fasted blood sample was taken from the cannula before consuming the drink. A timer 
was started and then blood samples (6 ml) were taken at 30, 60, 90 and 120 minutes 







Figure 7. A retrograde venous cannula inserted into the dorsal surface of an 
individual’s hand. 
A retrograde cannula is inserted in the opposite direction, towards the fingertips, to 
an anterograde cannula. The hand is then placed in a heated box and this allows 
bloods to be taken, where arterial venous shunting is more likely to occur, so that 
accurate metabolic measurements can be taken in a research setting (McGuire et al., 
1976). [Figure adapted from (Schumacher & Leonard, 2014)] 
 
From each blood sample taken, blood glucose, free fatty acids (FFA), plasma and 
insulin were measured. To do this, 10 ul of blood was taken for blood glucose to be 
analysed by the Biosen analyser. Then, at each time point the sample was split into 2 
vacutainers (VACUETTE, Greiner-Bio One, Gloucestershire, UK), one green (sodium 
heparin containing 30 µl EGTA-glutathionine which act as preservatives, improving 
the effective storage of red blood cells (Kucherenko & Bernhardt, 2015; Van’T Erve 
et al., 2014)) and one gold (serum). The green vacutainer was spun at 1800 RCF for 
10 minutes in a 4°C centrifuge (Eppendorf, 5702R, Stevenage UK). The supernatant 
was split into two microfuge tubes, one labelled FFA and the other labelled plasma. 
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The tube labelled FFA also had 5 µl tetrahydrolipstatin (THL) – a lipase inhibitor 
added to prevent degradation of the fatty acids (Hadvary et al., 1991; Krebs et al., 
2000). The blood in the gold vacutainer was allowed to clot for 15 minutes at room 
temperature before centrifugation. The gold vacutainer was then spun at 1800 RCF 
for 10 minutes in a 4°C centrifuge (Eppendorf, 5702R, Stevenage, UK). The 
supernatant was transferred to a microfuge tube labelled insulin. This generated a 
total of 15 microfuge tubes which were frozen at -80°C in the university laboratories 
to be further analysed.  
3.1.10. Glucose response curves 
 
Glucose response curves were constructed from the blood glucose concentrations, 
recorded at each time point by the Biosen analyser, using the computer software 
GraphPad Prism (GraphPad Software, Prism, California, USA). The shape of a 
glucose response curve can help determine the effect of the dose exercise on 
glycaemic control (Kaga et al., 2020). The area under the curve was calculated using 
the trapezoidal method within GraphPad Prism to allow for comparison between 
overall glucose concentrations during the OGTT after different energy expenditures 
(Allison et al., 1995).  
3.1.11. Coefficient of variation 
 
The coefficient of variation (CV) was calculated for the Biosen analyser and the Tanita 
scales to determine the variation in measurements. This allowed us to determine the 
accuracy of the equipment and therefore the precision of results (Reed et al., 2002). 
Multiple measurements of the same conditions were taken, and the following equation 
was used to calculate the accuracy of each measurement taken with each of these 
devices (Reed et al., 2002):  






Due to the Covid-19 pandemic, human testing was unable to place as it was deemed 
unsafe for both participants and the research team. This meant the clinical trial was 
postponed until May 2021 when ethical approval was given for 18-25 year old, healthy 
participants to take part in the protocol.  To mitigate the impact this had on my MSc by 
research, during the period which human testing was unable to take place, I undertook 
a systematic review, meta-analyses and meta-regressions on a topic similar to the 
clinical trial. Below are the methods used to carry out these analyses.  
3.2. Clinical trial - Results 
 
Due to the Covid-19 pandemic, human research was postponed to ensure the safety 
of participants and the research team. Government lockdown and tier-system 
restrictions prevented any laboratory access between the 14th October 2020 and 8th 
March 2021. Ethical approval was given on the 6th May 2021 to carry out the 
research on young healthy participants (18–25 year olds) who were at a lower risk of 
the serious implications of Covid-19. The research is in its early stages and therefore 
minimal data collection has occurred thus far. Four participants are currently enrolled 
and have started the protocol.  
3.2.1. Coefficient of variance 
 
Firstly, coefficient of variance (CV) calculations were carried out on a range of 
measurements taken within the protocol to ensure the equipment used provided 
accurate data. Repeat measures of BMI, weight, muscle mass, fat mass, blood 
glucose concentrations and blood lactate concentrations were recorded under the 






Table 2. Coefficient of variation (CV) values for a range of protocol measures.  
Values were calculated as a percentage for BMI, Body mass, Fat mass, Muscle 
mass, Blood glucose and Blood lactate. 
 
CV (%) 
BMI (kg/m2) 0.22 
Body mass (kg) 0.19 
Fat mass (kg) 0.79 
Muscle mass (kg) 0.1 
Blood glucose (mmol/L) 4.18 
Blood lactate (mmol/L) 3.97 
 
The four measures recorded on the Tanita Scales (BMI, Weight, Fat Mass, Muscle 
Mass) all gave coefficient of variation values <1 (0.22%, 0.19%, 0.79% and 0.1% 
respectively) (Table 2). The two measures recorded by the Biosen (blood glucose 
and lactate) both gave coefficient of variation values of <5 (4.18% and 3.97% 
respectively). 
3.2.2. OGTT results 
 
Three participants completed one exercise visit and OGTT, and one participant 
completed two exercise visits (no exercise and 350 kcal).  
Glucose concentrations were recorded every 30 minutes for a 2hr period and the 
recordings at each time point have been plotted to create glucose response curves 
(Figure 8). Figure 15a shows the response after no exercise and an area under the 
curve value of 739.9 mmol/L/120mins was calculated. Figure 15b shows the 
response after 350 kcal of exercise and an area under the curve value of 621.6 
mmol/L/120 minutes was calculated. The overall shapes of both curves are relatively 
similar, showing a similar overall response during the OGTT. Glucose concentration 
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peaks in the first 30 minutes after consumption of the dextrose drink, with the peak 
being around 8 mmol/L for 0 kcal energy expenditure (Figure 8a) and 7 mmol/L for 
350 kcal energy expenditure (Figure 8b). The glucose concentration then slowly 
decreases. For 350 kcal of exercise, the reduction in blood glucose concentration 
appears to plateau quicker at 90mins, whereas for 0 kcal energy expenditure, the 




Figure 8. Glucose Response Curves. A. OGTT results after 0kcal energy 
expenditure. B. OGTT results after 350kcal energy expenditure.  
These graphs plot glucose concentrations throughout OGTTs after exercise visits 
expending 0 kcal (control) and 350 kcal of energy . (A) the glucose response after 0 
kcal of exercise. (B)  the glucose response after 175 kcal of exercise. Area under the 
curve (AUC) values calculated using the trapezoidal method within GraphPad Prism, 
the average value of AUC glucose (AUC mmol/L/120mins) is presented. 
3.3. The Clinical Trial - Discussion 
 
The minimal data collected from the clinical trial was used to create glucose response 
curves of the 2hr OGTT glucose concentrations after two doses of exercise, 0 and 350 
kcal.  









The area under the curve (AUC) of the glucose response curves was calculated to 
determine the total change in glucose concentrations during the OGTT and to allow 
comparison of the two different energy expenditures of exercise. For no exercise prior 
to the OGTT, the AUC was 739.9 mmol/L/120mins. This decreased for 350 kcal of 
exercise 24 hours prior to the OGTT to an AUC of 621.6 mmol/L/120mins. These 
results had an extremely small sample size and therefore the reliability of them is 
unlikely to be high. However, these results support evidence from similar research 
carried out previously. For example, one clinical trial investigated the effects of 10 days 
of exercise in obese men (Angelopoulos et al., 2002). They concluded that the area 
under the curve of the results from an OGTT significantly differed between the exercise 
and control group from 944.6 mmol/L/120mins in the control group to 884.4 
mmol/L/120mins in the exercise intervention group (Angelopoulos et al., 2002). 
Another clinical trial investigated the effects of three levels of exercise activity on 
glucose response via an OGTT (Simper et al., 2020). They discovered similar results 
that exercise decreased the AUC, but they also found that the higher intensity and 
volume of exercise had the biggest decreases in the AUC (Simper et al., 2020). These 
results also give more evidence to suggest that the meta-regression using intensity 
and volume as moderators, may be more significant if a higher sample size and a 
larger range of exercise programmes were utilised within the analysis.  
However, there is some conflicting evidence within the literature as to whether 
any amount of exercise will result in a reduction in the AUC after an OGTT. One clinical 
trial found no significant difference between the AUC of the exercise intervention and 
the control (Potteiger et al., 2002). This could be due to the prescription and dose of 
exercise given to participants. More clarification could be given on this matter if the 
clinical trial continues to progress and data is collected on a higher sample size with 
all four doses of exercise (0, 175, 350, 700 kcal) being analysed. 
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The general shape of the glucose response curves (Figure 8) are similar to 
each other with glucose rising to a peak and then gradually beginning to decrease 
again. When compared to the typical shape of a glucose response curve in healthy 
individuals, the general shape of both curves is very similar (Arslanian et al., 2019), 
which suggests the participants are healthy in terms of glycaemic control. The two 
curves, of both doses of exercise (0 and 350 kcal), peak within the first 30 minutes of 
the OGTT. Evidence has shown that if glucose peaks after 30 minutes in an OGTT it 
is potentially indicative of prediabetes (Chung et al., 2017), further supporting the idea 
that the participants are healthy in regards to glycaemic control.  
The value at which glucose concentration peaks, decreases from 8.09 mmol/L 
in the OGTT after 0 kcal of exercise to 6.88 mmol/L in the OGTT after 350 kcal of 
exercise. This supports the idea that the acute effects of exercise on improving 
glycaemic control can still be experienced at least 24 hrs post-exercise (Van Dijk, 
Manders, et al., 2013). Evidence has shown that acute exercise increases the 
signalling of non-insulin dependent glucose signalling pathways and also increases the 
translocation of GLUT4 to the plasma membrane to ultimately increase glucose uptake 
(Röckl et al., 2008). The lower peak after 350 kcal of exercise may indicate that these 
changes are still present 24 hours post exercise. Therefore, this allows glucose uptake 
into cells to occur at a faster rate in the participants that undertake exercise prior to the 
OGTT which results in the lower peak plasma glucose concentrations.  
Interestingly, the glucose concentration at the 2-hour time point is lower 
following 0kcal energy expenditure (Figure 8a). For 0 kcal energy expenditure, the final 
glucose concentration is 3.76 mmol/L whereas for 350 kcal energy expenditure, the 
final glucose concentration is 4.12 mmol/L. This contradicts other research, which 
suggests in OGTTs after a bout of exercise, the final glucose concentration 
measurement is significantly lower than the final measure taken after no exercise 
(Angelopoulos et al., 2002). However, the OGTT results after 350 kcal are shown to 
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either plateau or slowly begin to peak again after the 90-minute time point (Figure 8b) 
so this could provide an explanation for the higher glucose concentration. Research 
has been carried out into identifying the shapes and the impacts of both monophasic 
and biphasic curves (Tschritter et al., 2003). Monophasic curves have one peak and 
then a gradual decrease of glucose concentration whereas biphasic curves have an 
initial peak and decrease, and then the glucose concentration begins to increase again 
(Figure 9) (Tschritter et al., 2003). This could suggest that the 0 kcal glucose response 
curve is monophasic due to the peak and then decrease in glucose concentration. The 
350 kcal glucose response curve could potentially be biphasic as there is an initial 
peak and decrease and then the glucose concentration could be gradually starting to 
increase after 90 mins. Evidence has also shown that biphasic curves are more 
indicative of improved insulin sensitivity (Kim et al., 2016; Tschritter et al., 2003). 
Therefore, this could suggest that insulin sensitivity has improved due to the 350 kcal 





Figure 9. Different shapes of glucose response curves after an OGTT. 
 A monophasic curve has a peak plasma glucose concentration and then a steady 
decline. A biphasic curve has an initial peak, plasma blood glucose concentrations 
begin to decline and then concentrations begin to increase again. [information to 
create figure taken from:(de Andrade Mesquita et al., 2018)] 
3.3.2. Coefficients of variation 
 
Coefficient of variation (CV) statistics are calculated to determine the 
reliability of the testing equipment used as this provides confidence that changes 
within the data are accurate and not just due to variation within the measurements 
taken using the equipment (Reed et al., 2002). To investigate this, coefficient of 
variation values were calculated for blood glucose and lactate concentrations 
recorded by the Biosen device, and also for BMI, weight, fat mass and muscle mass 
recorded by the bioimpedance scales (Tanita scales). All of the CV values for the 
measurements taken by the Tanita scales were less than 1%. This suggests that a 
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less than 1% change in the data is due to chance rather than the variables 
investigated (Reed et al., 2002). Therefore, if change is observed in the data higher 
than 1%, then it can be assumed that the data is reliable and indicative of change 
due to the intervention (Reed et al., 2002). The accuracy of the calculated CV values 
from the Tanita scales is supported by CV values calculated from the scales on other 
young healthy individuals (Pietrobelli et al., 2004)(Langer et al., 2016).  
The blood glucose and lactate concentrations determined using the Biosen 
had a higher percentage of variation than the Tanita scales but the CV values for 
both glucose and lactate measurements was still less than 5%. This is indicative of 
relatively low variation in the data due to the reliability of the equipment (Ospina & 
Marmolejo-Ramos, 2019) and suggests changes within data collected from this 
device greater than 5% are likely to be due to the interventions in place.  
3.3.3. Overall summary of the findings 
 
These results show that there could be an association in increased doses of 
exercise improving glycaemic control. However, due to the incomplete data set and 
low sample size, assumptions can only be made with support from existing literature. 
The coefficient of variation calculations demonstrate that, when more data is collected, 
the data is likely to be accurate and reliable due to the extremely small likelihood that 




One limitation of the research was with difficulties in retrograde cannulation, 
which prevented successful blood draws. This was typically due to the cannula being 
inserted near the vein wall, or due to insufficient pressure preventing blow flow out of 
the cannula (Cadamuro et al., 2015). Some of the blood taken from participants also 
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haemolysed which meant red blood cells had burst and the contents were released 
into the plasma and therefore it is likely that inaccurate data was recorded (Cadamuro 
et al., 2015). Once identified, changes were put in place to try and mitigate these issues 
such as readjusting the cannula after a test blood draw and using shorter connective 
kits which connect the cannula to a collection syringe. 
Another limitation of the research was in reducing subject bias within the 
protocol. It was difficult to blind participants to the dose of exercise they were 
completing as higher doses of exercise took a longer time to complete. It was also 
difficult to blind the research team as to which dose of exercise the random generator 
had generated for the participant to complete. This is because the investigator had to 
carry out calculations to determine the time required to exercise for that specific 
number of calories to be burnt, and they also had to set up the equipment to ensure 
the correct dose was completed. One way to reduce subject bias would be to not inform 
the participant of the dose of exercise they will be completing prior to them starting the 
exercise. Another way to reduce subject bias would be to get another member of the 
research team that isn’t collecting or analysing the results to randomise the dose of 
exercise and carry out the calculations to determine the length of time participants 
need to cycle for.  
As none of the participants were able to fully complete the protocol, the 
laboratory analyses on free fatty acid and insulin concentrations within the bloods 
taken for the OGTTs were not analysed. An understanding of FFA and insulin 
concentrations would be useful in determining the optimal doses of exercise required 
for participants to use an exercise programme for treatment. FFA concentrations have 
found to be significantly increased in obese individuals and individuals with type 2 
diabetes (Boden, 1999). This increase can be detrimental to the health of individuals, 
increasing both the risk of cardiovascular disease and the level of insulin resistance 
(Boden, 1999). Evidence suggests that both FFA concentrations and insulin sensitivity 
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can be improved through an exercise programme (Mika et al., 2019) and 
improvements in these factors could therefore contribute to improved glycaemic control 
in individuals with type 2 diabetes. FFA and insulin concentrations are therefore 
important factors to measure within this research. 
Finally, ensuring participants adhere to the requirements in the protocol relies 
mainly on trust. This includes participants not exercising for 72 hours prior to the visit, 
not consuming alcohol 48 hours prior, and only consuming the control meal 12 hours 
prior to the OGTT. All of these factors are likely to interfere with the data collected 
during the protocol. The use of an exercise tracker to measure their activity for a period 
before and after the exercise visit was one method put in place to monitor their activity 
levels. Blood glucose samples were taken before we began the OGTT to ensure the 
participant was suitably fasted. These measurements helped to ensure the glycaemic 
control measured during the OGTT was only in response to the dextrose drink and that 
changes seen in the OGTT were only due to the dose of exercise prescribed. 
3.3.5. Conclusions 
 
At the current stage, the study has been unable to successfully achieve its aims. From 
the data collected, the minimal dose of exercise to improve glycaemic control was 
unable to be determined. The results collected imply, with support from the current 
literature, that 350kcal of exercise has beneficial impacts on improving glycaemic 
control in young healthy individuals which is also likely to have similar benefits, if not 
greater benefits, on individuals with type 2 diabetes (Bird & Hawley, 2017). Due the 
importance of the research, discussed in section 2.11, the clinical trial will be 
encouraged to continue. This will allow the aims to be achieved and give a better 





3.3.6. Challenges of the research 
 
The Covid-19 pandemic had a major impact on this clinical trial. This is 
evidenced by the extremely small sample size and incomplete research protocol. 
Research was postponed until May 2021 as it was deemed unsafe due to the high risk 
it posed to both participants and the research team. Recruitment of young healthy 
participants was finally approved by the ethics committee and therefore recruitment 
began in May 2021. During the period which research was unable to take place, the 
systematic review, meta-analyses, and meta-regressions were completed. 
Recruitment after this point still proved to be difficult as individuals were 
cautious about attending the lab, even with Covid-19 safety precautions in place. There 
was also a number of individuals that had to postpone participating in the protocol due 
to having to isolate, as Covid-19 Delta variant cases began to rise in the area (Office 
for National Statistics, 2021). The number of people testing positive for Covid-19 in the 
north west increased from 0.45% on the 30th May 21 to 2.06% on the 7th August 21 
(Office for National Statistics, 2021) and therefore, just after ethical approval had been 
given to begin testing at the start of May 21, the progression of the trial was impacted 
again by Covid-19.  Four participants were initially recruited, three of which were 
university students who were no longer available out of term time from the beginning 
of July onwards. Recruitment was also made more difficult due to the reliance of the 
protocol on medics to cannulate volunteers who were extremely busy due to the high 
cases of Covid-19 in the area. Therefore, there were a number of weeks where no 





4. Meta-analysis  
4.1. Methods  
4.1.1. Aims and objectives 
 
The benefits of exercise for type 2 diabetes are well documented. However, the precise 
volume and intensity of exercise required to improve glycaemic control is unknown. 
Exercise is effective in helping to regulate glycaemic control in those with type 2 
diabetes, however, a meta-analysis hasn’t been completed since 2012 to analyse the 
impact of the dose of exercise on glycaemic control (Umpierre et al., 2013). The 
exclusion criteria for this meta-analysis narrowed down the papers retrieved from the 
search further, compared to the meta-analysis previously completed, and only included 
aerobic exercise programmes. This was done with the goal of minimising heterogeneity 
in the results. The aim of these meta-analyses and meta-regressions was to determine 
the impact of volume and intensity of exercise on glycaemic control in people with type 
2 diabetes. This was carried out by conducting a meta-analysis and then meta-
regression of studies examining the impact of volume and intensity on HbA1c 
concentrations in those with type 2 diabetes, using the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Page et al., 2021).  
  
4.1.2. Eligibility criteria 
 
This systematic review and meta-analysis were conducted in accordance with PRISMA 
guidelines (Page et al., 2021). Studies that met the following criteria were included in 
this meta-analysis: (1) published as a full-text manuscript; (2) not a review; (3) 
participants had type 2 diabetes (age >17 years); (4) studies were required to employ 
an intervention design and include a supervised aerobic exercise training period of ≥12 
weeks. Additionally, descriptive data (e.g., sample size, mean, and standard deviation) 
were required to be reported. Where this was not possible, details were requested from 
authors. The exclusion criteria was created to be more specific than the previous meta-
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analysis carried out (Umpierre et al., 2013). This meant, for example, only including 
aerobic exercise protocols and excluding protocols where individuals were taking 
alternative glucose lowering medication, such as metformin and corticosteroids. The 
primary aim was to investigate whether HbA1c was effected by aerobic exercise 
training and therefore we only included studies that measured HbA1c. Where an 
investigation took multiple measures such as BMI, fasting blood glucose, total 
cholesterol, triglycerides, LDL and HDL, we included them as separate datasets. 
 
HbA1c was chosen as the primary measure as it is now recommended as the standard 
of care for testing diabetes (Sherwani et al., 2016). HbA1c provides a reliable estimate 
of the patient’s blood glucose concentrations over a 3-month period as this is the 
average half-life of a red blood cell (Sherwani et al., 2016). Training programmes 
selected were therefore ≥12 weeks to ensure exercise could have an impact on and 
provide an accurate measurement of HbA1c concentrations. Ensuring that 
programmes were supervised increases the likelihood that participants successfully 
complete all the exercise training as stated in the methodology of the research paper. 
 
4.1.3. Information sources 
 
The following databases were identified and searched: MEDLINE (accessed by 
PubMed), Cochrane Central Register of Controlled Trials, Embase, and Web of 
Science. The literature search was completed up until 15th December 2020 and there 
was no start date. The search was performed within all fields and terms were “exercise 
AND glycaemic control”, “Type 2 Diabetes AND exercise”, and “exercise AND 
glycaemic control AND Type 2 diabetes AND randomised control trial”. The detailed 




4.1.4. Study selection 
 
The eligibility assessment was conducted by myself in an unblinded and standardised 
manner and was confirmed by a second independent researcher. Once each database 
search was completed and manuscripts were sourced, all studies were downloaded 
into a single reference list with duplicates removed. Titles and abstracts were then 
screened for eligibility and full texts were only retrieved for studies with HbA1c and a 
supervised exercise intervention incorporated. All studies retrieved as full texts were 
then thoroughly assessed using the complete eligibility criteria by myself and a second 
independent researcher confirming inclusion and exclusion.  
Additionally, retrieved full-text articles were classified using a PEDro (Physiotherapy 
Evidence Database) scale (Herbert et al., 2000). The PEDro scale is widely used to 
assess the internal validity of results and whether the level of statistical analysis allows 
the results to be interpretable (Albanese et al., 2020; de Morton, 2009). The score is 
rated out of 10 and depends on 11 different criteria, 1 (eligibility criteria) of which isn’t 
included in the score due to assessing the external rather than internal validity of the 
trial. The criteria includes; an eligibility criteria, random allocation, allocation 
concealment, similar starting baselines of participants, blinding of subjects, blinding of 
those administering the protocol, blinding of those taking measurements, 
measurements obtained from ≥85% of participants, ensuring subjects received 
treatment and control as allocated, between group statistical analysis for at least one 
outcome, and providing point measures and measures of variability for at least one 
outcome (Herbert et al., 2000). PEDro scores are provided in section 4, table 2. 
4.1.5. Data collection process 
 
Data were extracted for pre- and post-exercise HbA1c concentrations primarily. Then 
pre- and post- exercise BMI, fasting blood glucose, triglyceride, total cholesterol, HDL 
and LDL concentrations were extracted from papers which included these values. 
75 
 
Information on the number of participants, age of participants, trial period, number of 
exercise sessions each week and the length of each session was also recorded. In 
cases of missing data, authors were contacted via email and asked to provide 
necessary information. If no response was received, means and standard deviations 
(SDs) were estimated from figures using computer software (Image J, Maryland, USA). 
There were four requests sent for additional data and a two-week time frame for replies 
allowed for a response. No responses were received.  
 
The data for each variable was converted into the same units and if values were 













+ (𝑏 − 𝑎)2) 
Where a = lowest value, m = median and b = highest value 
 
The difference between pre- and post- exercise means and standard deviations was 
calculated ready for the meta-analysis to be carried out. If the change in standard 
deviation wasn’t available, it was calculated from the pre- and post- standard 





𝑓𝑖𝑛𝑎𝑙 − (2 𝑥 𝐶𝑜𝑟𝑟 𝑥 𝑆𝐷𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒𝑥 𝑆𝐷𝑓𝑖𝑛𝑎𝑙) 
 
Information, including changes in control mean, control standard deviation, control 
group sample size and exercise mean, exercise standard deviation and exercise group 
sample size for each variable, were imported into a spreadsheet within Jamovi (The 
Jamovi project (2021), Jamovi (Version 1.6) [Computer Software]) for the analysis to 
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take place. This software is specifically designed for meta-analyses. A random effects 
model of the meta-analysis with a tau2 estimator: maximum likelihood was calculated 
for each variable; HbA1c, fasting blood glucose, BMI, total cholesterol, triglycerides, 
HDL, and LDL. This software was used to produce forest plots to present the data and 
calculate standard mean differences (SMD) for each variable and the overall SMD of 
the meta-analysis. Funnel plots were created, and Egger’s regression values were 
calculated to assess the asymmetry of the results. The funnel plots plot the SMD 
(treatment effect) for individual studies on the horizontal access and the standard error 
on the vertical axis and this was then used to examine how effect sizes differed with 
the sample sizes, measured by the standard error of the studies (Song et al., 2002). 
Egger’s regression values were calculated within Jamovi to statistically examine 
whether asymmetry was present within the funnel plot (Sterne et al., 2000). Visual 
examination of the funnel plots and the statistical analysis using Egger’s regression 
can help identify whether any publication or associated bias is present within the data 
(Sterne et al., 2000). 
4.1.6. Meta-Regression 
 
Also using Jamovi, meta-regressions were carried out to try and establish if there was 
a dose-response relationship between intensity and volume on improvement in HbA1c 
i.e., if improvements in HbA1c were greater in higher intensity exercise or longer 
exercise interventions. To determine this, the intensity of the exercise sessions was 
calculated as a percentage of maximum exercise capacity. This measurement was 
chosen as the intensity stated in the research papers were expressed in different 
formats. Volume of exercise was calculated as the total dose of exercise undertaken 
throughout the programme and was calculated from the length of the exercise session, 




Random effects meta-regressions (continuous covariates) were then carried out to 
explore the association of volume and intensity of exercise with changes in HbA1c 
concentrations. Maximum exercise capacity (intensity) was input as a moderator into 
the analysis. A separate meta-regression was then produced using volume as a 
moderator to assess the effect of volume on HbA1c. A final meta-regression was 
produced which combined volume and intensity together to use as a moderator 
within the analysis. Meta-regression analyses were carried out in Jamovi and R (The 
R foundation (2021), R (version 4.1.0) [computer software] retrieved from 
https://cran.r-project.org), using the SMD estimates of HbA1c and the two exercise 
programme variables- intensity and volume. Scatter bubble plots were constructed 
graphically within R to display proportional weights of different trials. The code written 
by myself within R to carry out the analysis and create the bubble plots is presented 
below. The meta function was used to generate the initial meta-analysis. The 
metareg function of the Metafor package then used the meta-analysis and the 
covariate (moderator) as the input (Harrer et al., 2021). Bubble plots were then 
created using the function bubble to show the predicted regression slope with the y 
axis representing the SMD of HbA1c and the x axis representing the moderator, the 
size of the bubble depends on the weight of each study (Harrer et al., 2021). R2* 
values were also calculated for each regression analysis run to examine the amount 
of variability within the effect size of HbA1c which can be accounted for by the model 
(each of the moderators) (Hamilton et al., 2015). It was calculated using the equation 
below (Harrer et al., 2021). 









Code written to carry out meta-regression analysis and create bubble plots in R: 
file.choose() 






meta1<-metacont(mean.e=ex.mean, sd.e=ex.sd, n.e=ex.sample.size, 
mean.c=ï..control.mean, sd.c=control.SD, n.c=control.sample.size, studlab=author, 
data=data1, sm="SMD") 
meta2<-metareg(meta1, ~intensity) 
bubble(meta2, studlab=data1$author, xlim=c(0.4, 0.8), ylim=c(-8.5, 2), 
main="bubbleplot") 
meta3<-metareg(meta1, ~volume) 
bubble(meta3, studlab=data1$author, xlim=c(-30, 125), ylim=c(-8.5, 2), 
main="bubbleplot")  
meta4<-metareg(meta6, ~volumexintenisty) 
bubble(meta4, studlab=data1$author, xlim=c(-30, 100), ylim=c(-8.5, 2), 
main="bubbleplot") 
4.1.7. Data items 
 
Heterogeneity was quantified with the I2 statistic and through the analysis of the funnel 
plots created. An I2 value of 25% may be interpreted as low, 50% as moderate and 
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75% as high between study heterogeneity (Higgins et al., 2003). A random-effect meta-
analysis was carried out on aerobic exercise protocols. Data extracted from each study 
included: study sample size, intervention/control group descriptions, study design, 
analysis method, and outcome data. Outliers were excluded if they had a studentised 
residual larger than the 100 x (1 - 0.05/(2 X k))th percentile of a standard normal 
distribution (Ranganai, 2016). Methodological quality was assessed using the modified 
0-10 PEDro scale (de Morton, 2009). The primary outcome variables were defined as 
HbA1c pre- and post-intervention. Standardised mean differences (SMD) were 
retrieved for inclusion into the meta-analysis. Further analyses were performed based 
on research design as a means of investigating heterogeneous results. Random 
effects meta-regressions (continuous covariates) were carried out to explore the 
association of volume (total volume) and intensity of exercise (maximum exercise 
capacity) with changes in HbA1c concentrations. Scatter bubble plots were 
constructed graphically to display proportional weights of different trials and R2* values 
were calculated.  
 
4.2. Results  
 
This research consisted of both a systematic review including a meta-analysis with 
meta-regression and a clinical trial to investigate the effects of different doses of 
exercise on glycaemic control and to help examine exercise as a treatment. The clinical 
trial was postponed due to the Covid-19 pandemic until May 2021 and is therefore in 
the early stages of research where human testing on young healthy participants has 
only just begun. 




Both a meta-analysis and meta-regression were carried out to investigate the 
effects of volume and intenstiy of exercise programmes on HbA1c concentrations and 
ultimately glycaemic control. In the meta-regression, intensity and volume of exercise 
were used as modifiers to identify the specific effects of these factors on HbA1c 
concentrations. 
4.2.2. Study selection 
 
After the initial database search, 5364 records were identified (Figure 10). Once 
duplicates were removed, 3775 titles and abstracts were screened for inclusion, 
resulting in 190 studies being retrieved as full text and assessed for eligibility. Of those, 
174 were excluded and 20 articles remained, and due to missing details 16 studies 
were used in the final quantitative synthesis. To assess publication bias, funnel plots 
were computed and Egger’s regression value was calculated to statistically analyse 




Figure 10. PRISMA flow diagram of studies included in the systematic review.  
Studies were identified through database searching and then compiled into a 
spreadsheet. Duplicates were removed and articles were screened via title and 
abstracts. Full texts were then assessed, and this resulted in 16 studies being 





4.2.3. Trial setting and participants 
 
The exercise programme settings included university health or research 
departments, community-based exercise facilities and large public hospitals. The 
number of participants in each clinical trial ranged from n = 19 to n = 251 (Belli et al., 
2011; Sigal et al., 2007). One trial included only female participants (Belli et al., 2011) 
and one trial included only male participants (Yan et al., 2014). All trials were carried 
out on adults and the age of participants ranged from 30-75 years. Baseline HbA1c 
(%) ranged from an average of 6.7% (Backx et al., 2011) to 8.8% (Yan et al., 2014) for 
all trials included. The intensity of the exercise programmes (as % total exercise 
capacity) ranged from 50% (Ku et al., 2010) to 75% (Balducci et al., 2010; Jorge et al., 
2011) and the total volume of exercise for the programme ranged from 9 hours (20-
37.5 min 3 d/week for 16 weeks) (Alvarez et al., 2016) to 390 hours (50 mins 3-5 
d/week for 39 weeks) (Sénéchal et al., 2013).   
4.2.4. Interventions 
 
A description of the exercise programmes included is given (Table 3). The 
duration of interventions ranged from 12 weeks to 52 weeks, with a median of 12 
weeks. The studies mainly included aerobic exercise in the form of cycling, jogging, 
and walking. 75% of the studies included had three exercise sessions per week, two 
interventions had only two sessions per week (Emerenziani et al., 2015)(Balducci et 
al., 2010) and two interventions had up to five sessions per week (Ku et al., 2010; 
Sénéchal et al., 2013). Each exercise session lasted between 12 minutes and 1 hour, 






Table 3. Description of included studies and data sets.  
Descriptions of studies included in the meta-analyses and meta-regressions. Details 
of the exercise interventions included within the study programme, design method, 
outcome measures recorded, number of participants and the PEDro score of the trial. 
MEC= maximum exercise capacity, RCT = randomised control trial; HbA1c = 
Glycated Haemoglobin, BMI = body mass index, LDL = low-density lipoprotein, HDL 
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4.2.5. Synthesis of results 
 
Of the 16 studies included, all were randomised control trials (RCTs). Where a 
study had multiple conditions, they were treated separately. 
4.2.6. Glycaemic control  
 
HbA1c reflects a cumulative history of an individual’s blood glucose levels 
during the previous 2-3 months, due to the half-life of a red blood cell being around 12 
weeks (Sherwani et al., 2016).  This meta-analysis investigated changes in HbA1c (as 
the gold-standard measure) in response to regular supervised aerobic exercise to 
determine the impact on glycaemic control. All 16 trials provided data on HbA1c. The 
individual mean difference of pre-post changes in HbA1c in control and aerobic groups, 
respectively, ranged from -1.2% to 1.1% (median = -0.09%) and -1.3% to 0.1% 
(median = -0.51%). Standardised mean difference (SMD) of within-group change in 
HbA1c between control and aerobic groups in each of the trials ranged from -0.39 to 
2.18, with 88% of trials showing a positive change towards reducing HbA1c. The 
pooled summary estimate of standardised mean difference of within-group change in 
HbA1c between control and aerobic groups was 0.56 (95% CI 0.3 – 0.82) with p <0.001 
(Figure 11), favouring aerobic exercise over control for reducing HbA1c concentration. 
There was considerable heterogeneity in this meta-analysis (I2= 61.05%, p <0.001) 
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and the funnel plot shows potential asymmetry (Figure 11b) with Egger’s regression 






Figure 11. Meta-analysis of HbA1c. 
(a) Forest plot comparing the effects of exercise on HbA1c concentrations (SMD). A 
positive value represents a bigger difference in the SMD between exercise and 
control group, indicating that exercise reduces HbA1c. (b) Funnel plot of studies 
evaluating the effect of exercise on HbA1c.  
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Fasting blood glucose measures the plasma glucose concentration after a 
period without food consumption (Bouma et al., 1999). This helps to examine the 
change in the exact glucose concentration between the start and end of the exercise 
programme (Bouma et al., 1999). Although this may not be representative of the 
average long-term change in glycaemic control like HbA1c, it was used in this meta-
analysis as a second line of evidence to support the results indicated by HbA1c 
(Bouma et al., 1999). Eight trials recorded fasting blood glucose concentrations and 
one trial was removed due to being a large outlier in the data set (Alvarez et al., 2016). 
Therefore, seven trials were included in this meta-analysis. The individual mean 
difference of pre-post changes in fasting blood glucose in control and aerobic groups, 
respectively, ranged from -1.35 mmol/L to 0.6 mmol/L (median = 0.5 mmol/L) and -
1.53 mmol/L to 0.15 mmol/L (median= -0.99 mmol/L). SMD of within-group change in 
fasting blood glucose between control and aerobic groups in each of the trials ranged 
from -0.21 to 1.77, with 75% of trials showing a positive change towards reducing 
fasting blood glucose. The pooled summary estimate of the standardised mean 
difference of within-group change in fasting blood glucose between control and aerobic 
groups was 0.76 (95% CI 0.23 – 1.3) with p < 0.05 (Figure 12), showing a significant 
reduction in fasting blood glucose with exercise programmes. There was considerable 
heterogeneity in this meta-analysis (I2= 76.67%, p <0.001). Examination of the funnel 
plot (Figure 12b) and Egger’s regression value (Egger’s regression value = -0.72, p 





Figure 12. Meta-analysis of fasting blood glucose. 
(a). Forest plot comparing the effects of exercise on fasting blood glucose 
concentrations (SMD). A positive value represents a bigger difference in the SMD 
between exercise and control group, indicating that exercise reduces fasting blood 




4.2.7. Body Mass Index 
 
Improvements in glycaemic control are often associated with weight loss and 
decreases in BMI but there’s some debate as to whether they are directly correlated 
(Franz, 2007). 13 trials recorded the change in BMI after the exercise programme and 
this meta-analysis was therefore carried out on 13 trials. The individual mean 
difference of pre-post changes in BMI in control and aerobic groups, respectively, 
ranged from -0.7 kg/m2 to 0.4 kg/m2 (median = -0.1 kg/m2) and -2.2 kg/m2 to 0.21 kg/m2 
(median = -0.8 kg/m2). SMD of within-group change in BMI between control and 
aerobic groups in each of the trials ranged from -0.53 to 2.97, with 85% of studies 
showing a positive value in respect to reducing BMI. The pooled summary estimate of 
the standardised mean difference of within-group change in BMI between control and 
aerobic groups was 0.76 (95% CI 0.25 – 1.27) with p <0.05, and therefore the exercise 
programmes significantly reduced BMI (Figure 13). There was considerable 
heterogeneity in this meta-analysis (I2= 86.35 %, p <0.001) and asymmetry was 
present after examination of the funnel plot (Figure 13b) and calculation of Egger’s 










Figure 13. Meta-analysis of BMI. 
Forest plot comparing the effects of exercise on BMI concentrations (SMD). A 
positive value represents a bigger difference in the SMD between exercise and 
control group, indicating that exercise reduces BMI. (b) Funnel plot of studies 
evaluating the effect of exercise on BMI. 
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4.2.8. Lipid Profiles- Triglycerides 
 
This meta-analysis analysed the effect supervised aerobic exercise 
programmes have on triglyceride concentrations in those with type 2 diabetes to 
investigate how significantly exercise can be used as a treatment. Eight trials recorded 
triglyceride concentrations and one trial was removed due to being a large outlier 
(Balducci et al., 2010). This meta-analysis was therefore carried out on seven trials. 
The individual mean difference of pre-post changes in triglyceride concentration in 
control and aerobic groups, respectively, ranged from -0.58 mmol/L to 0.2 mmol/L 
(median = -0.05 mmol/L) and -0.48 mmol/L to 0 mmol/L (median = -0.16mmol/L). SMD 
of within-group change in triglycerides between control and aerobic groups in each of 
the trials ranged from -0.33 to 0.84, with 86% of studies showing a positive result in 
reducing triglyceride concentration. The pooled summary estimate of the standardised 
mean difference of within-group change in triglycerides between control and aerobic 
groups was 0.15 (95% CI -0.08 – 0.38) with p >0.05 (Figure 14). Thus, the exercise 
programmes did not significantly reduce triglyceride concentrations. There was no 
heterogeneity in the meta-analysis (I2= 0%, p >0.05) and no asymmetry was found 
after examination of the funnel plot (Figure 14b) and calculation of Egger’s regression 






Figure 14. Meta-analysis of triglyceride concentrations. 
  (a) Forest plot comparing the effects of exercise on triglyceride concentrations 
(SMD). A positive value represents a bigger difference in the SMD between exercise 
and control group, indicating that exercise reduces triglycerides.  (b) Funnel plot of 
studies evaluating the effect of exercise on triglycerides. 
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4.2.9. Lipid Profiles- Total Cholesterol 
 
Total cholesterol is analysed within this meta-analysis to investigate whether 
the concentration in individuals with type 2 diabetes changes after a period of 
supervised aerobic exercise. 11 trials reported total cholesterol concentration and 
three trials were removed due to being large outliers (Alvarez et al., 2016; Balducci et 
al., 2010; Yavari et al., 2010). This meta-analysis was therefore carried out on eight 
trials. The individual mean difference of pre-post changes in total cholesterol 
concentration in control and aerobic groups, respectively, ranged from -0.35 mmol/L 
to 0.33 mmol/L (median = 0.05 mmol/L) and -0.7 mmol/L to 0.16 mmol/L (median = -
0.11 mmol/L). SMD of within-group change in total cholesterol between control and 
aerobic groups in each of the trials ranged from -0.39 to 0.95. The pooled summary 
estimate of the standardised mean difference of within-group change in total 
cholesterol between control and aerobic groups was 0.09 (95% CI -0.13 – 0.31) with p 
>0.05, and therefore the exercise programmes did not significantly reduce total 
cholesterol (Figure 15a). There was no substantial heterogeneity in this meta-analysis 
(I2= 0%, p >0.05) and examination of the funnel plot and Egger’s regression value 
(Egger’s regression value = 0.742, p >0.05) indicate that asymmetry wasn’t present 
within the results. 
4.2.10. Lipid Profiles- High Density Lipoprotein 
 
This meta-analysis investigates whether a period of supervised aerobic 
exercise has beneficial effects on increasing HDL and reducing the risk of 
cardiovascular disease. 10 trials recorded high density lipoprotein (HDL) 
concentrations and one trial was removed due to being a large outlier. This meta-
analysis was therefore carried out on nine trials. The individual mean difference of pre-
post changes in HDL concentration in control and aerobic groups, respectively, ranged 
from -0.06 mmol/L to 0.2 mmol/L (median = 0.02 mmol/L) and -0.15 mmol/L to 0.5 
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mmol/L (median = 0.07 mmol/L). SMD in within-group change in HDL between control 
and aerobic groups in each of the trials ranged from -0.38 to 0.47. The pooled summary 
estimate of the standardised mean difference of within-group change in HDL between 
control and aerobic groups was -0.05 (95% CI -0.25 – 0.16) with p >0.05, and therefore 
the exercise programmes did not significantly change HDL concentrations (Figure15b). 
There was considerable heterogeneity in this meta-analysis (I2= 83.08%, p < 0.001). 
After examination of the funnel plot produced and Egger’s regression value (Egger’s 
regression value = -0.123, p >0.05) no asymmetry was found to be present within the 
results. 
4.2.11. Lipid Profiles- Low Density Lipoprotein 
 
LDL is investigated within this meta-analysis to examine whether a programme of 
aerobic exercise reduces the increased concentrations of LDL resultant of obesity 
and therefore type 2 diabetes as a secondary component (Lazarte & Hegele, 2020). 
Nine trials recorded low density lipoprotein concentrations and therefore this meta-
analysis included nine trials. The individual mean difference of pre-post changes in 
LDL concentration in control and aerobic groups, respectively, ranged from -0.83 
mmol/L to 0.09 mmol/L (median = -0.06 mmol/L) and -1.3 mmol/L to 0.35 mmol/L 
(median = -0.125 mmol/L). SMD of within-group change in LDL between control and 
aerobic groups in each of the trials ranged from -2.01 to 1.93. The pooled summary 
estimate of the standardised mean difference of within-group change in LDL between 
control and aerobic groups was 0.12 (95% CI -0.55 – 0.79) with p >0.05, and 
therefore the exercise programmes did not significantly change LDL (Figure 15c). 
There was considerable heterogeneity in this meta-analysis (I2= 88.31%, p <0.001). 
After examination of the funnel plot and Egger’s regression value (Egger’s regression 





Figure 15. Meta-analysis of total cholesterol, HDL, and LDL concentrations.  
(a) Forest plot comparing the effects of exercise on total cholesterol concentrations 
(SMD). (b) Forest plot comparing the effects of exercise on HDL concentrations 






Meta-regression analyses are useful for understanding the effect of modifiers, such as 
variables within exercise programmes, on changes within outcomes measures within 
the trials. Meta-regression analyses were carried out to explore the association of 
volume and intensity with changes in HbA1c concentrations. This was to understand 
whether there was a relationship between increases in intensity and decreases in 
HbA1c, increases in volume and decreases in HbA1c, and a combination of intensity 
and volume and the impact this has on HbA1c. All these analyses were weighted by 
the inverse of the variance of each observation and scatter bubble plots were 
constructed to graphically display proportional weights of different trials. Intensity, 
volume, and volume x intensity had no significant relationship with changes in HbA1c 
(p = 0.96, 0.116 and 0.602, respectively) (Figure 16) and the results showed moderate 
heterogeneity (I2 = 60.92%, 58.63% and 60.93%). The R2* values, showing how much 
variability within HbA1c could be accounted for by the moderators, were 1.25%, 









Figure 16. Meta-regression of (a) intensity, (b) volume, and (c) intensity x 
volume on HbA1c. 
 Bubble plots showing the association of (a) intensity, (b) volume and (c) intensity x 
volume of exercise on HbA1c concentrations after a programme of exercise. The 
values are plot in relation to the moderators on the x axis and the SMD of HbA1c on 


















4.3. Discussion- Meta-analysis and meta-regression 
 
4.3.1. Glycaemic control 
 
HbA1c significantly decreased in those with type 2 diabetes after ≥12 weeks of 
supervised exercise. This meta-analysis showed that 87.5% of exercise interventions 
reduced HbA1c concentrations. The overall HbA1c SMD of the aerobic exercise 
interventions was 0.56 (95% CI 0.3 – 0.82) which indicates that the exercise  
programme is around 0.5 times more effective in decreasing HbA1c concentrations 
than the control group (Faraone, 2008). Exercise programmes of ≥12 weeks help 
regulate glycaemic control and are therefore likely to be beneficial in treating the 
disease and helping to reduce the risk of comorbidities. Contracting muscles require 
larger amounts of glucose and delivery to muscle cells is increased due to a rise in 
blood flow (Sylow et al., 2017). Capillary recruitment is upregulated which increases 
the surface area for glucose uptake into cells (Sylow et al., 2017). The improvement 
in glucose uptake could be mediated through two pathways. Exercise does not 
require PI3K to prompt GLUT-4 translocation and thus, insulin resistant tissue will still 
take up glucose during exercise (Sylow et al., 2017). Intracellular Ca2+ concentrations 
increase significantly within contracting muscles (Röckl et al., 2008), along with ROS 
and PKC concentrations increasing (Stanford & Goodyear, 2014). These molecules 
are able to activate a range of signalling cascades (Stanford & Goodyear, 2014). 
Evidence shows Ca2+ increases the expression of GLUT4 genes, it does this via 
increased Ca2+/calmodulin signalling. AS160-phospho- Akt substrate site and 
TBC1D1 phosphorylation occur as a result of this signalling (Stanford & Goodyear, 
2014), increasing the availability of GLUT4 at the surface (Chin, 2005). The 
increased translocation of GLUT4 allows glucose transport to increase. The cell then 
utilises this glucose to produce energy for muscle contraction which maintains the 
diffusion gradient for glucose influx into the cell (Sylow et al., 2017). All of these 
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factors contribute to reduced plasma glucose concentrations which will subsequently 
reduce concentrations of HbA1c. This demonstrates an understanding of the 
mechanisms involved in how exercise lowers the high blood glucose concentrations 
associated with type 2 diabetes, and evidence for this is provided by the reductions in 
HbA1c seen in this meta-analysis.   
 If the exercise programme is completed regularly and maintained, for example 
for 12 weeks or more, then the body begins to adapt to become better equipped to 
deal with exercise (Colberg et al., 2010). The expression and activity of proteins 
involved in the insulin signalling pathway increases which improves insulin sensitivity 
(Colberg et al., 2010). Evidence has shown that even periods of exercise of only 6 
weeks improve insulin sensitivity (Koivisto & Yki-Järvinen, 1986) and therefore, this 
could provide another explanation for how exercise contributes to reductions in HbA1c 
as seen in this meta-analysis. 
Adiposity is strongly linked to insulin resistance, and therefore weight loss induced 
by the exercise programme (indicated through a reduction in BMI) may increase insulin 
sensitivity. Regular exercise utilises the higher concentrations of glucose and lipids in 
those who are overweight and have type 2 diabetes (Yang et al., 2019). This helps 
reduce the glucotoxicity and lipotoxicity that cells are exposed to, helping to improve 
insulin sensitivity (Yang et al., 2019). This allows insulin to work more effectively in 
providing glycaemic control and could be an additional explanation for the reduction in 
HbA1c.  
One of the major consequences’ individuals with type 2 diabetes experience due high 
blood glucose concentrations is both macro- and micro- vascular complications 
(Fowler, 2011). Around 20% of people in the UK with diabetes experience a 
macrovascular complication, and these complications account for 59% of deaths in 
those individuals (Turner, 1998). Improvements in glycaemic control have been shown 
to significantly reduce the risk of morbidities and improve the outcomes of those with 
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type 2 diabetes (Schinner, 2009). The evidence provided in this meta-analysis, that 
exercise significantly reduces HbA1c, shows that exercise can be used as a treatment 
of type 2 diabetes and also a preventative measure against other morbidities. This 
aligns well with other research which have also concluded that exercise can be used 
as a preventative measure by improving glycaemic control (Colberg et al., 2010; De 
Lade et al., 2016; Larose et al., 2011; Najafipour et al., 2017). 
Metformin is one of the most common drugs used to treat type 2 diabetes and it is 
usually given as an initial treatment to help regulate HbA1c concentrations (American 
Diabetes Association, 2017). However, it is associated with side effects, including 
gastrointestinal intolerance, vitamin B12 deficiency and the worsening of the effects of 
nephropathy (American Diabetes Association, 2017). It is also unlikely to prevent the 
progression of the disease and therefore after a few years, it is likely to be used in 
combination with other pharmacological therapies, including insulin and 
secretagogues, both of which are associated with their own side effects (American 
Diabetes Association, 2017). Using exercise as an alternative has a range of benefits, 
both acutely and chronically, improving blood glucose control, improving insulin 
sensitivity, reducing cardiovascular disease risk, and ultimately reducing the risk of 
mortality, accompanied by minimal side effects (Colberg et al., 2010). Therefore, 
understanding the dose-response to exercise and the minimal amount of exercise 
required to provide improved glycaemic control so it can be used as an effective 
treatment will be extremely beneficial in reducing the reliance on pharmacological 
treatments, reducing the risk of morbidities and the cost of medication, ultimately 
reducing the overall burden on healthcare systems.  
Fasting blood glucose also significantly changed after an exercise programme of 
≥12 weeks with 75% of studies included in the meta-analysis demonstrating a lowering 
of fasting blood glucose. It is likely to be statistically significant as it shows blood 
glucose concentrations as a reflection of the momentary situation pre- and post- 
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exercise programme and this demonstrates blood glucose concentrations reduced 
after the exercise programme (Bouma et al., 1999). However, it is an acute 
measurement parameter and is therefore only indicative of glucose concentrations at 
the exact point of measurement, rather than an average change throughout like HbA1c 
(Bouma et al., 1999). The standard of care for monitoring diabetes, recommended by 
the American Diabetes Association, is HbA1c due to its direct correlation with average 
plasma glucose concentrations (Sherwani et al., 2016). The 75% of studies that 
showed a decrease in blood glucose concentrations help to support the evidence 
provided by HbA1c, that exercise programmes improve glycaemic control in those with 
type 2 diabetes. 
 
4.3.2. HbA1c and BMI association 
 
The BMI of participants significantly decreased by 0.6 kg/m2 after the exercise 
programme of ≥12 weeks. People with type 2 diabetes typically have a higher BMI, 
including increased visceral adiposity (Eckel et al., 2011). The average BMI of 
participants at the beginning of the trials included in this meta-analysis was 30.1 kg/m2 
and 80% of studies included showed a significant decrease in BMI after the exercise 
programme by 2.1% on average. The overall BMI SMD of the aerobic exercise 
interventions was 0.76 (95% CI 0.25 – 1.27), which suggests that the exercise 
programmes significantly decrease BMI by a magnitude of 0.76 times more than the 
no exercise control group.  In those with type 2 diabetes, even small reductions (around 
5%) in body mass have shown to have significant impacts on improving glycaemic 
control (Wilding, 2014). For example, a 0.1% reduction in HbA1c has been found with 
each 1 kg of body mass lost in patients with the disease (Gummesson et al., 2017). 
Improvements in BMI have also been associated with reducing the risk of mortality 
from comorbidities, such as cardiovascular disease (Wilding, 2014). Weight loss has 
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been associated with a 25% reduction in overall mortality risk in those with type 2 
diabetes, and a 28% reduction in the risk of mortality from cardiovascular disease 
(CVD) after a 12-year prospective analysis study on 4970 overweight individuals with 
the disease (Williamson et al., 2000). Evidence suggests weight loss by increased 
energy output can reduce lipid profiles, including total cholesterol, HDL, LDL and 
triglycerides, in overweight individuals at high risk of CVD, such as those with type 2 
diabetes (Ryan & Yockey, 2017). Evidence for significant improvements in cholesterol 
concentrations has been found when approximately 7% weight loss is maintained 
(Ryan & Yockey, 2017). This meta-analysis therefore provides further evidence that 
exercise programmes of ≥12 weeks, which have beneficial impacts on weight loss, can 
also reduce the risk of comorbidities and secondary complications associated with the 
disease.   
4.3.3. Lipid profiles 
 
Out of all the lipid profiles analysed, none changed significantly at the p <0.05 level, 
with SMD also showing little change. This suggests that these exercise programmes 
did not have a beneficial impact on total cholesterol, triglyceride, HDL, and LDL 
concentrations. There is variation in the evidence from other meta-analyses as to 
whether exercise programmes significantly improve lipid profiles (Kelley & Kelley, 
2007; Yoo & Lee, 2005). One meta-analysis found that aerobic exercise only 
significantly changed LDL concentrations and non-significant changes were found in 
total cholesterol, triglyceride, and HDL concentrations (Kelley & Kelley, 2007). Total 
cholesterol, HDL, and LDL all significantly changed in another meta-analysis (Yoo & 
Lee, 2005) and this was supported by evidence from another meta-analysis showing 
positive changes in both LDL and HDL (Hayashino et al., 2012). The variation in the 
results of all these meta-analyses could be due to differences in exclusion criteria. For 
example, two of the meta-analyses included both aerobic and resistance exercise 
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(Hayashino et al., 2012; Yoo & Lee, 2005), whereas this meta-analysis and one other 
only included aerobic exercise trials (Kelley & Kelley, 2007). 
Evidence has found that exercise programmes reduce the concentration of small 
dense lipid particles and increase the concentration of large, less dense particles which 
is most significantly seen in LDL (Wang & Xu, 2017). This is likely to reduce the risk of 
cardiovascular disease as larger, less dense particles are less atherosclerotic (Wang 
& Xu, 2017). Therefore, beneficial changes might be found in the structure and 
composition of lipid particles rather than overall concentrations (Kelley & Kelley, 2007).  
Other factors which might contribute to the lack of significance, at the p< 0.05 level, in 
these meta-analyses are the variations in programme length, and volume, frequency 
and intensity of exercise prescribed to participants within the trials included. From the 
analysis, HDL and LDL show a large amount of heterogeneity (I2 = 83.08% and 88.31% 
respectively) which could further support the idea that the variation within programme 
prescription might impact the significance seen in these results (Biau et al., 2008). 
Total cholesterol and triglyceride concentrations show low heterogeneity (I2 = 0%) 
which implies that all studies have the same effect.  
Evidence has found that total energy expenditure and intensity are key factors in 
determining the impact an exercise programme has on lipid profiles (S. Mann et al., 
2014). Longer programmes at high intensity have been shown to reduce total 
cholesterol and increase HDL cholesterol concentrations (Dunn et al., 1997) and 
evidence for this is seen within some of the trials included within this meta-analysis. 
For example, one trial (Yavari et al., 2010) carried out a protocol for 52 weeks, with 3 
sessions per week at an average intensity of 67.5%. The SMD for this trial was 1.72 
providing evidence that this longer and higher intensity programme reduced total 
cholesterol concentrations when compared with the control group. A shorter 
programme but at a higher intensity has been suggested to reduce triglyceride 
concentrations and increase HDL concentrations (LeMura et al., 2000), and therefore 
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demonstrates the conflict within the literature as to what dose of exercise is optimal for 
individuals in regards to lipid profiles.  The most significant improvements are seen in 
high volume and high intensity programmes (Kraus et al., 2002).  
The intensity of the exercise programmes included in this meta-analysis varies from 
50-75% of total exercise capacity, and the volume of exercise within the programme 
varies between 9 hours and 390 hours in total, ranging from 12 mins 3x per week for 
16 weeks (Alvarez et al., 2016) to 50 mins 3x per week for 40 weeks (Sénéchal et al., 
2013). HDL, LDL, BMI, fasting blood glucose and HbA1c meta-analyses all 
demonstrate substantial statistical heterogeneity, and this means there is variation 
within the analysis that isn’t due to chance. This is likely due to differences within the 
protocols of each trial, including differences in intensity, volume, and type of aerobic 
exercise. One way in which this heterogeneity could be investigated is by carrying out 
a meta-regression using volume and intensity as modifiers and this was investigated 
next. 
4.3.4. Association of HbA1c with Intensity and Volume 
 
A meta-regression was carried out on HbA1c using intensity and volume as 
moderators to investigate the effects these variables could have on glycaemic control. 
When used as separate moderators, intensity, and volume were not significantly 
associated with HbA1c concentrations (p = 0.96 and 0.116, respectively). However, 
both variables also have moderate heterogeneity within the results (I2 = 60.92% and 
58.63%). This could be due to variations within exercise programmes. Confidence in 
the conclusions could be improved by having a bigger sample size available to use 
within the meta-regression. For the effects of exercise programmes to be better 
investigated within the meta-regression, trials need to investigate a bigger range of 
intensities. The trials included only range in intensity from 50-75% with a big proportion 
of exercise programmes ranging between intensities of 60-70%, this is therefore 
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unlikely to give the true association of intensity with HbA1c. A meta-analysis 
investigating the difference between high intensity interval training (HIIT) and moderate 
intensity interval training (MIIT) found that HIIT at 85-95% max HR showed a 0.37% 
greater reduction in HbA1c than MIIT (Liu et al., 2019). Further supporting the idea that 
exercise intensity in this meta-regression might be too low to show an association.  
However, the literature is conflicting as to whether increases in intensity have 
a significant effect on decreasing HbA1c concentrations. For example, one clinical trial 
investigated the effects of exercise programmes with the same energy expenditure but 
different intensities of exercise (Hansen et al., 2009). They found that both groups (low-
moderate intensity and moderate-high intensity) had equal effects in reducing HbA1c 
concentrations (Hansen et al., 2009). Another clinical trial supports this idea as 
moderate and high intensity interval exercise resulted in non-significant differences in 
reductions in HbA1c (Ahmad, 2019). This poses the question as to whether it is the 
lower volume of high intensity exercise that acts as the limiting factor because high 
intensity exercise can’t be maintained for long periods (Hansen et al., 2009). A meta-
regression was therefore carried out to investigate volume as a moderator. 
The volume of exercise was a non-significant moderator of HbA1c, p = 0.116 
and R2*= 25.45% which shows that 25% of the variation within the effect size of HbA1c 
was accounted for by volume (Harrer et al., 2021). Even though the results weren’t 
statistically significant when the p value is taken into account, there is a trend within 
the data due to R2*= 25.45% and this could be because the analysis was too 
underpowered to show an effect (Suresh & Chandrashekara, 2012). A power value of 
27% was calculated in the computer software Jamovi. This suggests that there’s only 
a 27% chance that this meta-regression would correctly report a statistically significant 
result (Suresh & Chandrashekara, 2012). There could therefore be a potential 
association between increasing volume and improvements in glycaemic control but a 
lack of studies available to be included within the analysis could mean the analysis 
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was too underpowered to show significance (Suresh & Chandrashekara, 2012). More 
confident conclusions could be made if a larger number of trials with a larger sample 
size were investigated. A previous meta-analysis, even though it has a slightly different 
exclusion criteria, found from 18 studies that aerobic exercise ≥150mins/week was 
associated with greater reductions in HbA1c (Umpierre et al., 2011). This supports the 
suggestion that higher volumes might be significantly correlated to decreases in HbA1c 
and this should be an area for further research.  
A meta-regression was carried out combining volume and intensity as a 
moderator to investigate the association with HbA1c. The results of this meta-
regression were also non-significant, likely due to the reasons stated above. 
4.3.5. Limitations 
 
While the literature assessment was comprehensive, it is possible that studies may 
have been missed from the analysis. There was significant heterogeneity in a range of 
measures included, this indicates variation in the data which could be caused by both 
clinical diversity or methodological diversity. The exercise programmes vary between 
trials and therefore this could account for clinical diversity. Methodological diversity is 
shown by the varying PEDro scores (Table 2). However, the inclusion and exclusion 
criteria used for these meta-analyses was created with providing sufficient 
homogeneity between studies in mind. Whilst random effects modelling was also 
chosen to mitigate this effect, this remains a limitation. Some analyses included have 
achieved statistical significance, however the change to be considered clinically 
relevant remains to be fully determined.  
Publication bias could also be a limitation of these meta-analyses. Both the meta-
analyses of HbA1c and BMI showed asymmetry after visual analysis of the funnel plots 
and statistical analysis with Egger’s regression values. This indicates that ‘small-study 
effects’ could be present due to bias, such as publication bias, and heterogeneity within 
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the studies, contributing to smaller studies presenting larger treatment effects (Song 
et al., 2002; Sterne et al., 2000). There are a range of reasons why this might have 
occurred.  
Significant results are more likely to be cited within the literature, especially in the area 
of medical research and if the language is in English (Devito & Goldacre, 2019; Sterne 
et al., 2000). This encourages and biases editors towards publishing research with 
significant findings, and researchers are less likely to submit research with non-
significant findings for publication (Devito & Goldacre, 2019). This results in an inability 
to accurately analyse the true range of data and therefore it becomes difficult to make 
confident conclusions in the findings (Devito & Goldacre, 2019). An attempt to mitigate 
and analyse the impacts of publication bias was made within these meta-analyses by 
producing funnel plots and calculating Egger’s regression values to identify any 
asymmetry within the data (Song et al., 2002). Another method which could be used 
within meta-analyses to take into account publication bias is p-uniform calculations, 
but this can overestimate effect sizes in analyses with considerable heterogeneity and 
therefore should be used with caution (McShane et al., 2016). An inclusion of a range 
of studies published in different languages could also potentially reduce the bias in 
meta-analyses but this relies on access to individuals who are able to translate articles 
in other languages (Sterne et al., 2000). 
Open Science is growing in popularity and this could be extremely beneficial in 
reducing publication bias within systematic reviews, meta-analyses and meta-
regressions (Allen & Mehler, 2019). It requires the preregistration of methodology, 
analyses and hypotheses to be made publicly accessible prior to data collection, and 
aims to increase the scientific validity of research and also the chance of null findings 
being published (Allen & Mehler, 2019). It would therefore allow a more accurate 






Although there is substantial evidence indicating the benefits of aerobic exercise 
as a treatment for those with type 2 diabetes, there is still insufficient evidence on the 
exact intensity, volume and duration of exercise required to provide optimal glycaemic 
control. This analysis suggested that increases in intensity didn’t have greater benefits 
on glycaemic control, but there was a substantial association (R2*=25%) between 
increases in volume and improvements in glycaemic control. Investigation into the 
optimal volume of exercise to treat type 2 diabetes could therefore be an interesting 
and extremely beneficial area of further research. This systematic review and meta-
analysis provide evidence that short-term interventions begin to show improvements 
in glycaemic control, but long-term interventions are likely to be required to provide 
significant beneficial changes in lipid profiles. Therefore, future long-term studies are 
needed to provide accurate conclusions on the minimum duration, intensity and 
volume of aerobic exercise needed to treat type 2 diabetes. 
Future research 
 
To further investigate the impact of volume and intensity of exercise on glycaemic 
control in individuals with type 2 diabetes, clinical trials need to be carried out on a 
larger range of volumes and intensities of exercise. This will allow another meta-
regression to be carried out with a higher study sample size and a wider range of 
results to be analysed. This will give a clearer understanding as to whether there are 
associations with volume of exercise in particular, but also intensity of exercise, and 
glycaemic control. Another idea for future research related to findings from the meta-
analysis, would be to analyse the lipid profiles of individuals who take part in exercise 
programmes for a long period (>12 months). This would allow conclusions to be made 
as to whether exercise has to be maintained for longer periods for beneficial 
improvements in lipid profiles to be experienced. There is also conflict within the 
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literature as to what form of exercise will provide the best improvements in glycaemic 
control and treatment for individuals with type 2 diabetes. A future meta-regression 
could therefore compare the responses of different types of exercise, including aerobic, 
resistance, a combination of both, on glycaemic control to give further clarification of 
which would be most beneficial. 
The clinical trial will hopefully continue now that Covid-19 restrictions have 
eased, and vaccinations have successfully rolled out. This will allow the sample size 
to increase and data to be collected across the full range of energy expenditures of 
exercise. A dose-response relationship between exercise and glycaemic control will 
then be determined which, if successful, will allow the minimum dose of exercise 
required to treat type 2 diabetes to be better understood. Continuous glucose monitor 
(CGM) data, and data on insulin and free fatty acids would also be encouraged to be 
collected within the protocol to ensure the range of beneficial effects of exercise as a 
treatment can be understood. If individuals understand the range of benefits of 
exercise and also, the minimal dose of exercise they need to complete for it to provide 
effective glycaemic control, then they will be more likely to participate in exercise and 
hopefully maintain this within the long term.  
In addition to this clinical trial, it would also be useful to investigate the impacts 
of a multi-modal treatment plan including nutrition, well-being, and educational advice. 
This would help us better investigate the combination of methods to treat type 2 
diabetes which would be most beneficial. One potential idea would be to carry out a 
retrospective study comparing the treatment regimes put in place at different 
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Q2. Are you a current smoker?  
      If yes, how many cigarettes do you smoker per day? ______________ 
       
      If no, have you ever smoked? 
      If yes, how long has it been since you quit? _____________________ 









Q3. Family history: Have any parents or siblings had a heart attack, 
       bypass surgery, angioplasty or sudden death* prior to 55 years (male  
       relatives) or 65 years (female relatives)? 
       If yes, please circle what they had. 
Yes No 
Q4. What is your ethnicity?  
       Please provide here _______________________________________ 
 
Q5. Sport (if applicable): ________________  
 
 
Q6. Physical activity: In the past year, have you engaged in a regular 
strength training programme including the front and back squat? 
  
Yes No 
Q7. Body Size: Weight  __________ kg 
                          Height   __________ cm                   
                          Body Fat %                                                  Males 
                                                                                                Females 













Figure 17.  Screening Questionnaire. 
 A number of questions asked to participants based on personal and family history, 
and lifestyle habits, used to determine whether participants were at a low risk and 
safe to participate. Questions based on the American College of Sports Medicine 
(ACSM) readiness to exercise criteria. 
 
 
*Advise to visit GP Question highlighted in blue will be completed after measurement taken 
Personal History of Disease 
Q10.  Heart disease Yes No 
Q11.  Peripheral vascular disease Yes No 
Q12.  Cerebrovascular disease (e.g. stroke) Yes No 
Q13.  Asthma Yes No 
Q14.  Chronic obstructive pulmonary disease Yes No 
Q15.  Diabetes mellitus                                                                   Type 1       





Q16. Thyroid disorder Yes No 
Q17. Renal (kidney) disease Yes No 
Q18. Liver disease Yes No 
Q19. Musculoskeletal conditions                                           Osteoarthritis  
                                                                                    Rheumatoid arthritis 







Q20. Any other condition? Please provide details ___________________ 
        ______________________________________________________ 
Yes No 
Q20. Do you have an injury that may be worsened with exercise? 
         If so, please provide details ______________________________ 
        _____________________________________________________ 
Yes No 
Q21. Are you taking any prescribed or non-prescribed medications/drugs? 
        If so, please provide details ______________________________ 




Q9. Have you had any alcohol to drink in the last 24 hours? 
      If yes, how many units? ______________ units 
                 how long ago? ________________ hours 
Yes No 
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